ВСЕРОССИЙСКИЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО КОНТРОЛЮ НАД РИСКОМ ВНЕЗАПНОЙ ОСТАНОВКИ СЕРДЦА И ВНЕЗАПНОЙ СЕРДЕЧНОЙ СМЕРТИ, ПРОФИЛАКТИКЕ И ОКАЗАНИЮ ПЕРВОЙ ПОМОЩИ

внезапная смерть, внезапная сердечная смерть, врожденный порок сердца, дефибриллятор, рекомендации, сердечная недостаточность, имплантируемый кардиовертер-дефибриллятор, инфаркт миокарда, острый коронарный синдром, сердечная ресинхронизирующая терапия, кардиомиопатия реанимация, стабильная ишемическая болезнь сердца, внезапная сердечная смерть, тахикардия, поражение клапанов сердца

1. Zipes D.P., Camm A.J., Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 2099-2140.

2. Priori S.G., Blomstrom-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015 Nov 1; 36(41): 2793-867.

3. Ревишвили А.Ш. Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств» 3-е изд., доп. и перераб. - М.: МАКС Пресс, 2013. - 596 с.

4. Monsieurs KG, Nolan JP, Bossaert LL et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 1. Executive summary. Resuscitation 2015; 95: 1-80.

5. Pedersen CT, Kay GN, Katman J et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014; 16: 1257-1283.

6. Vardas P.E., Auricchio A., Blanc J.J. et al. European Society of Cardiology, European Heart Rhythm Association. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007; 9: 959-998.

7. Epstein A.E., DiMarco J.P., Elenbogen K.A. et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coil Cardiol 2008; 51: el -62.

8. Goldberger J.J., Cain M.E., Hohnloser S.H. et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiotogy and Prevention. Circulation 2008; 118: 1497-1518.

9. Dickstein K., Vardas P.E., Auricchio A. et al. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010; 12: 1143-1153.

10. McMurray J.J., Adamopoutos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 2012; 33: 1787-1847.

11. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Orculation 2013; 128: 1810-1852.

12. Brignole M., Auricchio A., Baron-Esquivias G. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34: 2281-2329.

13. Epstein A.E., DiMarco J.P., Etlenbogen K.A. et al. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for devicebased therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013; 127: e283-352.

14. Kusumoto F.M., Calkins H., Boehmer J. et al. HRS/ACC/AHA expert consensus statement on the use of imptantabte cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.J Am Colt Cardiol 2014; 64: 1143-1177.

15. Windecker S., Koth P., Alfonso F. et al. 2014 ESC/ EACTS Guidelines on myocardial revascutarization: the Task Force on Myocardial Revascutarization of the European Society of Cardiotogy (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.

16. Priori S.G., Wilde A.A., Horie M. et al. Executive summary: HRS/ EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013; 15: 13891406.

17. Fishman G.I., Chugh S.S., Dimarco J.P. et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010; 122: 2335-2348.

18. Томилин В.В., Бережной Р.В., Сергеев С.Н. К вопросу о скоропостижной смерти лиц молодого возраста. Судебно-медицинская экспертиза. 1980; № 1: с. 16-20.

19. Byard R.W., Ranson D., Krous H.F., Workshop P. National Australian workshop consensus on the definition of SIDS and initiation of a uniform autopsy approach to unexpected infant and early childhood death. Forensic Sci Med Pathol 2005; 1: 289-292.

20. Basso C., Burke M., Fornes P. et al. Association for European Cardiovascular P. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch 2008; 452: 11-18.

21. Priori S., Schwartz P., Bardy G. et al. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95: 265-272.

22. Niemeijer M.N., van den Berg M.E., Leening M.J. et al. Declining incidence of sudden cardiac death from 1990 2010 in a general middle-aged and e[derly population: the Rotterdam Study. Heart Rhythm 2015; 12: 123 - 129.

23. Mendis S.P.P., Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.

24. Eckart R.E., Shry E.A., Burke A.P. et al. Department of Defense Cardiovascular Death Registry G. Sudden death in young adults: an autopsy-based series of a population undergoing active su rveillance. J Am Coil Cardiol 2011; 58: 1254-1261.

25. van der Werf C., Hendrix A. et al. Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community-based intervention study. Europace 2015 Apr 1. pii: euv059.

26. United Nations Economic Commission for Europe. UNECE statistical database (http://w3.unece.org/pxweb).

27. AHA Statistical Update Heart Disease and Stroke Statistics-2016 Update A Report From the American Heart Association Circulation. 2016; 133: e38-e360.

28. Линчак Р.М., Недбайкин А.М., Семенцова Е.В. и др. Частота и структура внезапной сердечной смертности трудоспособного населения Брянской области. Данные регистра ГЕРМИНА (реГистр внЕзапной сеРдечной сМертности трудоспособного населенИя бряНской облАсти). Рациональная фармакотерапия в кардиологии. 2016; 12(1): 45-50.

29. Макаров Л.М., Комолятова В.Н., Киселева И.И., Солохин Ю.А. Распространённость внезапной сердечной смерти у лиц молодого возраста в крупном мегаполисе - Медицинский алфавит - 2014/3 - Кардиология № 1 - с. 35-40.

30. Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. Внезапная сердечная смерть. - М.: ГЭОТАР-Медиа, 2011. - 267 с.

31. Van Camp S.P., Bloor C.M., Mueller F.O. et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exert 1995; 27: 641-647.

32. Corrado D., Basso C., Rizzoli Get al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003; 42: 1959 - 1963.

33. Maron B.J., Doerer J.J., Haas TSet al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 1 |9: 1085-1092.

34. Choi K., Pan Y.P., Pock M., Chang R.K. Active surveillance of sudden cardiac death in young athletes by periodic Intemet searches. Pediatr Cardiot 2013; 34: 1816-1822.

35. Suarez-Mier M.P., Aguilera B., Mosquera R.M., Sanchezde-Leon MS. Pathology of sudden death during recreational sports in Spain. Forensic Sci Int 2013; 226: 188-196.

36. Maron B.J., Haas T.S., Murphy C.J. et al. Incidence and causes of sudden death in U.S. coUege athletes. J Am Col[ Cardiol 2014; 63: 1636-1643.

37. Topaz O., Edwards J.E. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985; 87: 476-482.

38. Drory Y., Turetz Y., Hiss Y. et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68: 1388-1392.

39. Wisten A., Forsberg H., Krantz P., Messner T. Sudden cardiac death in 15-35-year olds in Sweden during 1992-99.J Intern Med 2002; 252: 529-536.

40. Eckart R.E., Scoville S.L., Campbell et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004; 141: 829 -834.

41. Puranik R., Chow C.K., Duflou J.A. et al. Sudden death in the young. Heart Rhythm 2005; 2: 1277-1282.

42. di Gioia C.R., Autore C., Romeo D.I.M. et al. Sudden cardiac death in younger adults: autopsy diagnosis as a tool for preventive medicine. Hum Pathol 2006; 37: 794-801.

43. Papadakis M., Sharma S., Cox S. et al. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace 2009; 11: 1353-1358.

44. Morris V.B, Keelan T., Leen E. et al. Sudden cardiac death in the young: a 1-year post-mortem analysis in the Republic of Ireland. Ir J Med Sci 2009; 178: 257-261.

45. Lira Z, Gibbs K, Ports JE, Sanatani S. A review of sudden unexpected death in the young in British Columbia. Can J Cardiol 2010; 26: 22-26.

46. Winkel B.G., Hoist A.G., Theilade J. et al. Nationwide study of sudden cardiac death in persons aged 1 - 35 years. Eur Heart J 2011; 32: 983 -990.

47. Margey R., Roy A., Tobin S. et al. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. Europace 2011; 13: 1411-1418.

48. Pilmer C.M., Porter B., Kirsh J.A. et al. Scope and nature of sudden cardiac death before age 40 in Ontario: a report from the cardiac death advisory committee of the office of the chief coroner. Heart Rhythm 2013; 10: 517-523.

49. de Noronha S.V., Behr E.R., Papadakis M. et al. The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths. Europace 2014; 16: 899-907.

50. Risgaard B., Winke B.G., Jabbari R. et al. Burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark. Circ Arrhythm Electrophysiol 2014; 7: 205-211.

51. Winkel B.G., Risgaard B., Sadjadieh G., et al. Sudden cardiac death in children (1-18 years): symptoms and causes of death in a nationwide setting. Eur Heart J 2014; 35: 868- 875.

52. Pilmer C.M., Kirsh J.A., Hildebrandt D. et al. Sudden cardiac death in children and adolescents between 1 and 19 years of age. Heart Rhythm 2014; 11: 239-245.

53. Vassalini M., Verzeletti A., Restori M., De Ferrari F. An autopsy study of sudden cardiac death in persons aged 1-40 years in Brescia (Italy).J Cardiovasc Med 2015; 16: [Epub ahead of print].

54. Mazzanti A., O’Rourke S., Ng K., Miceli C., et al. The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. Expert Rev Car-diovasc Ther 2014; 12: 499-519.

55. Maron B.J. Sudden death in young athletes. N EngIJ Med 2003; 349: 1064-1075.

56. Basso C., Carturan E., Pilichou K. et al. Sudden cardiac death with normal heart: molecular autopsy. Cardiovasc Pathot 2010; 19: 321-325.

57. Tester D.J., Medeiros-Domingo A., Will M.L. et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsynegative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87: 524-539.

58. Приказ Минздрава РФ от 24.04.2003 N 161 “Об утверждении Инструкции по организации и производству экспертных исследований в бюро судебно-медицинской экспертизы” (Зарегистрировано в Минюсте РФ 02.06.2003 N 4616).

59. Ackerman M.J., Priori S.G., Willems S. et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 2011; 13: 1077-1109.

60. Wellens H.J., Schwartz P.J., Lindemans F.W. et al. Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J 2014; 35: 1642-1651.

61. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992; 85: 12-10.

62. Lloyd-Jones D.M., Wilson P.W., Larson M.G. et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94: 20 - 24.

63. Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.

64. Jouven X., Desnos M., Guerot C., Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978 - 1983.

65. Friedlander Y., Siscovick D.S., Weinmann S. et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998; 77: 155-160.

66. Dekker L.R., Bezzina C.R., Henriques J.P. et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006; 114: 1140-1145.

67. Kaikkonen K.S., Kortelainen M.L., Linna E., Huikuri H.V. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006; 114: 1462-1467.

68. Bezzina C.R., Pazoki R., Bardai A. et al. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet 2010; 42: 688-691.

69. Arking D.E., Junttila M.J., Goyette P. et al. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet 2011; 7: e1002158.

70. Moss A.J., Zareba W., Hall W.J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N EngIJ Med 2002; 346: 877-883.

71. Bardy G.H., Lee K.L., Mark D.B. et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an imptantabte cardioverter-defibrittator for congestive heart failure. N EngI J Med 2005; 352: 225-237.

72. Scott P.A., Barry J., Roberts P.R., Morgan J.M. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-anatysis. EurJ Heart Fail 2009; 11: 958-966.

73. Levine Y.C., Rosenberg M.A., Mittteman M. et al. B-type natriuretic peptide is a major predictor of ventricutar tachyarrhythmias. Heart Rhythm 2014; 11: 1109-1116.

74. Priori S.G., Schwartz P.J., Napolitano C. et al. Risk stratification in the tong-QT syndrome. N Engl J Med 2003; 348: 1866-1874.

75. Школьникова М.А., Харлап М.С., Ильдарова Р.А. Генетически детерминированные нарушения ритма сердца. Российский кардиологический журнал. 2011. - № 1 (87). С. 8-25.

76. Spirito P., BeUone P., Harris K.M. et al. Magnitude of left ventricutar hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N EngI J Med 2000; 342: 1778-1785.

77. Barsheshet A., Goldenberg I., O-Uchi J. et al. Mutations in cytoplasmic toops of the KCNQ1 channet and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 tong-QT syndrome. Circulation 2012; 125: 1988-1996.

78. Moss A.J., Zareba W., Kaufman E.S. Increased risk of arrhythmic events in tong-QT syndrome with mutations in the pore region of the human ether-a-go-go-retated gene potassium channel. Circulation 2002; 105: 794-799.

79. van Rijsingen I.A., Arbustini E., Elliott P.M. et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study.JAm Coil Cardio12012; 59: 493-500.

80. Yoshinaga M., Ushinohama H., Sato S. et al. Etectrocardiographic screening of 1-month-old infants for identifying protonged QT intervals. Circ Arrhythm Electrophysiol 2013; 6: 932-938.

81. Yoshinaga M., Kucho Y., Sarantuya J. et al. Genetic characteristics of children and adotescents with tong-QT syndrome diagnosed by school-based electrocardiographic screening programs. Circ Arrhythm Electrophysiol 2014; 7: 107-112.

82. Schwartz P.J., Stramba-Badiate M., Crotti L. et al. Prevalence of the congenital Iong-QT syndrome. Circulation 2009; 120: 1761-1767.

83. Corrado D., Petticcia A., Bjornstad H.H. et al. Cardiovascular pre-participation screening of young competitive athtetes for prevention of sudden death: proposat for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 516-524.

84. Maron B.J., Thompson P.D., Ackerman M.J. et al. Recommendations and considerations related to preparticipation screening for cardiovascutar abnormalities in competitive athtetes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physicat Activity, and Metabolism: endorsed by the American Coltege of Cardiology Foundation. Circulation 2007; 115: 1643 - 1455.

85. Ljungqvist A., Jenoure P., Engebretsen L., et al. The International Olympic Committee (IOC) consensus statement on periodic health evaluation of etite athletes, March 2009. BrJ Sports Meal 2009; 43: 631-643.

86. Steinvil A., Chundadze T., Zeltser D. et al. Mandatory etectrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking? J Am Coll Cardiol 2011; 57: 1291-1296.

87. Narain R., Dhutia H., Merghani A. et al. Preventing sudden cardiac death in the young: results from a population-based screening program in the UK. European Journal of Preventive Cardiology 2014; 21: suppl S1-S6.

88. Kattman J.R., Thompson P.D., Lantos J. et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and brood institute working group. Circulation 2011; 123: 1911-1918.

89. James C.A., Bhonsale A., Tichnetl et al. Exercise increases age-related penetrance and arrhythmic risk in ar-rhythmogenic right ventricutar dysptasia/cardiomyopa-thy-associated desmosomal mutation carriers. J Am Coil Cardiol 2013; 62: 1290-1297.

90. Sawant A.C., Bhonsale A., te Riele A.S.J.M. et al. Exercise has a disproportionate role in the pathogenesis of arrhyth-mogenic right ventricular dysptasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc 2014; 3: e001471.

91. Приказ Министерства здравоохранения Российской Федерации от 3 февраля 2015 г. No 36ан «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения».

92. Приложение № 1 к приказу Министерству здравоохранения Российской Федерации от 21 декабря 2012 г. N 1346н «О порядке прохождения несовершеннолетними медицинских осмотров, в том числе при поступлении в образовательные учреждения и в период обучения в них».

93. Школьникова М.А. Первичные электрические заболевания серца как причина внезапной смерти. Док-тор.т. 2008; 3: 25-32.

94. Behr E.R., Datageorgou C., Christiansen M. et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur Heart J 2008; 29: 1670-1680.

95. Charron P., Arad M., Arbustini E. et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardiat Diseases. Eur Heart J 2010; 31: 2715 - 2726.

96. Christiaans I., Birnie E., Bonsel G.J. et al. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. EurJ Hum Genet 2008; 16: 1201-1207.

97. Ormondroyd E., Oates S., Parker I., Blair E., Watkins H. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. EurJ Hum Genet 2014; 22: 88-93.

98. Ingles J., Yeates L., Hunt L. et al. Health status of cardiac genetic disease patients and their at-risk retatives. IntJ Cardiol 2013; 165: 448-453.

99. Battista R.N., Blancquaert I., Laberge A.M. et al. Genetics in health care: an overview of current and emerging models. Public Health Genomics 2012; 15: 34-45.

100. Ingles J., Lind J.M., Phongsavan P., Semsarian C. Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet Meal 2008; 10: 117-120.

101. Christiaans I., van Langen I.M., Birnie E. et al. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. AmJ Med Genet A 2009; 149A: 602-612.

102. McGorrian C., Constant O., Harper N. et al. Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome. Europace 2013; 15: 1050-1058.

103. Макаров Л.М., Комолятова В.Н., Куприянова О.О. и соавт. Национальные российские рекомендации по применению методики холтеровского мониторирования в клинической практике. Российский кардиологический журнал 2014, 2 (106): 6-71.

104. Moya A., Sutton R., Ammirati F. et al. Guidelines for the diagnosis and management of syncope. Eur Heart J 2009; 30: 2631-2671.

105. George S., Rodriguez I., Ipe D. et al. Computerized extraction of electrocardiograms from continuous 12-lead Holter recordings reduces measurement variability in a thorough QT study. J Clin Pharmacol 2012; 52: 18911900.

106. Verrier R., Klingenheben T., Malik M, et al. Microvolt T-Wave Alternans. Physiological Basis, Methods of Measurement, and Clinical Utility-Consensus Guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol 2011; 58: 1309-1324.

107. Schmidt G., Malik M., Barthel P. et al. Heart rate turbulence after ventricular premature beats as predictor of mortality after acute myocardial infarction. Lancet, 1999; 353: 130-196.

108. de Asmundis C., Conte G., Sieira J. et al. Comparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace 2014; 16: 1231-1235.

109. Volosin K., Stadler R.W., Wyszynski R., Kirchhof P. Tachycardia detection performance of implantable Loop recorders: results from a large ‘real-life’ patient cohort and patients with induced ventricular arrhythmias. Europace 2013; 15: 1215-1222.

110. М.А. Школьникова, Т.А. Вахмистрова, Л.А. Кравцова и др. Эффективность ревил-диагностики причин потери сознания у детей. Кардиология. 2012, № 9, Том 52, с. 36-43.

111. Polyakova E.B., Trofimova T.A., Shkolnikova M.A. Efficacy of implantable loop recorder in children with structurally normal heart and unexplained syncope, long QT syndrome and congenital heart diseases. Eur Heart J Table of Contents for ESC Congress 2016 27 - 31 August Rome, Italy August, 2016; Vol. 37, suppl 1.

112. Kamath G.S., Zareba W., Delaney J. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8: 256-262.

113. Nava A., Folino A.F., Bauce B., et al. Thiene G. Signal-averaged electrocardiogram in patients with arrhyth-mogenic right ventricular cardiomyopathy and ventricular arrhythmias. Eur Heart J 2000; 21: 58-65.

114. Gibbons R.J., Balady G.J., Bricker J.T. et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Colt Cardiol 2002; 48: 1531-1540.

115. Podrid P.J., Graboys T.B. Exercise stress testing in the management of cardiac rhythm disorders. Med Clin North Am 1984; 68: 1139 - 1152.

116. Prastaro M., D’Amore C., Paolillo S. et al. Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Fail Rev 2015; 28: 305-316.

117. Chiu D.T., Shapiro N.I., Sun B.C., Mottley J.L., Grossman S.A. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation. J Emerg Med 2014; 47: 113 - 118.

118. Zellweger M.J., Hachamovitch R., Kang X. et al. Th reshold, incidence, and predictors of prognostically highrisk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nud Cardiol 2009; 16: 193 -200.

119. Kang X., Berman D.S., Lewin H. et al. Comparative ability of myocardial perfusion singLe-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes meUitus. Am Heart J 1999; 137: 949-957.

120. Zelias A., Stepinska J., Andres J. et al. Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography. Kardiol Pol 2014; 72: 687-699.

121. Zaman S., Narayan A., Thiagalingam A. et al. Significance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction. Pacing Clin Electrophysiol 2014; 37: 795-802.

122. Brembilla-Perrot B., Suty-Selton C., Houriez P. et al. Value of non-invasive and invasive studies in patients with bundle branch block, syncope and history of myocardial infarction. Europace 2001; 3: 187-194.

123. Dechering D.G., Kochhauser S., Wasmer K. et al. Elec-trophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10: 158-164.

124. Pelliccia A., Maron B.J., Culasso F. et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation. 2000; 102: 278-284.

125. Marine J.E., Sherry V., Chow G.V. et al. Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging). J Am CoU Cardiol 2013; 62: 595 -600.

126. Cheitlin M.D., Armstrong W.F., Aurigemma G.P. et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am CoU Cardiol 2003; 42: 954-970.

127. Brignole M., Menozzi C., Moya A. et al. International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with bundle branch block and negative electrophysioLogical test. Circulation 2001; 104: 2045-2050.

128. Denes P., Uretz E., Ezri M.D., Borbola J. CLinicaL predictors of electrophysiologic findings in patients with syncope of unknown origin. Arch Intern Med 1988; 148: 1922-1928.

129. Roguin A., Bomma C.S., Nasir K. et al. Implantable cardioverterdefibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coil Cardiol 2004; 43: 1843 - 1852.

130. Bhonsale A., James C.A., Tichnell C. et al. Incidence and predictors of implantable cardioverter-defibrilLator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardio-verter-defibrillator implantation for primary prevention. J Am Coil Cardiol 2011; 58: 1485 - 1496.

131. Goldberger J.J., Subacius H., Patel T. et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy.J Am Coil Cardiol 2014; 63: 1879-1889.

132. Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-2779.

133. Bhandari A.K., Shapiro W.A. et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985; 71: 63-71.

134. Giustetto C., Schimpf R., Mazzanti A. et al. Long-term follow-up of patients with short QT syndrome.J Am COIl Cardiol 2011; 58: 587-595.

135. Mazzanti A., Kanthan A., Monteforte N. et al. Novel insight into the natural history of short QT syndrome.JAm Coil Cardiol 2014; 63: 1300-1308.

136. Brugada J., Brugada R., Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092-3096.

137. Middlekauff H.R., Stevenson W.G., Stevenson L.W., Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope.J Am Coil Cardio11993; 21: 110-116.

138. Boutitie F., BoisseL J.P., Connolly S.J. et al. Amioda-rone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268-2275.

139. Amiodarone Trials Meta Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.

140. Ray W.A., Murray K.T., Meredith S. et al. Oral erythromycin and the risk of sudden death from cardiac causes. N EngIJ Med 2004; 351: 1089-1096.

141. Mosholder A.D., Mathew J., Alexander J.J. et al. CardiovascuLar risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368: 1665-1668.

142. Belardinelli L., Giles W.R., Rajamani S. et al. Cardiac late Na(-F) current: proarrhythmic effects, roles in Long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm 2015; 12: 440-448.

143. Sarganas G., Garbe E., Klimpel A. et al. Epidemiology of symptomatic drug-induced Long QT syndrome and torsade de pointes in Germany. Europace 2014; 16: 101-108.

144. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N EngIJ Med 1989; 321: 406-412.

145. Kontos M.C., Diercks D.B., Ho P.M. et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology’s NCDR. Am Heart J 2011; 161: 864-870.

146. Echt D.S., Liebson P.R., Mitchell L.B. et al. CAST Investigators. MortaLity and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N EnglJ Med 1991; 324: 781-788.

147. Singh S.N., Fletcher R.D., Fisher S.G. et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.

148. Piccini J.P., Berger J.S., O’Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 38: 1245-1253.

149. Singh B.N., Singh S.N., Reda D.J. et al. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.

150. Lafuente-Lafuente C., Longas-Tejero M.A., Bergmann J.F., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5: CD005049.

151. Kuhlkamp V., Mewis C., Mermi J. et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment-J Am Coil Cardio11999; 33: 46- 52.

152. Waldo A.L., Carom A.J., deRuyter H. et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Su rvival With Oral d-Sotalol. Lancet 1996; 348: 7-12.

153. Hohnloser S.H., Dorian P., Roberts R. et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114: 104-109.

154. Bunch T.J., Mahapatra S., Murdock D. et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol 2011; 34: 1600 - 1606.

155. Pacifico A., Hohnloser S.H., Williams JH et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N EngI J Med 1999; 348: 1855-1862.

156. Goyal A., Spertus J.A., Gosch K. et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307: 157-164.

157. Alberte C., Zipes D.P. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol 2003; 14: S87-S95.

158. Pitt B., Remme W., Zannad F. et al. Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N EngIJ Med 2003; 348: 1309-1321.

159. Dries D.L., Domanski M.J., Waclawiw M.A., Gersh B.J. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. AmJ Cardio11997; 79: 909-913.

160. Mitchell L.B., Powell J.L., Gillis A.M. et al. Are lipidlowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial./Am Coil Cardiol 2003; 42: 81-87.

161. Smith T., Jordaens L., Theuns D.A. et al. The costeffec-tiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J 2013; 34: 211-219.

162. Goldenberg I., Gillespie J., Moss A.J. et al. Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010; 122: 1265-1271.

163. Goldenberg I., Kutyifa V., Klein H.U. et al. Survival with cardiac-resynchronization therapy in mild heart failure. N EngIJ Med 2014; 370: 1694-1701.

164. Garnreiter J.M., Pilcher T.A., Etheridge S.P., Saarel E.V. Inappropriate ICD shocks in pediatrics and congenital heart disease patients: Risk factors and programming strategies. Heart Rhythm 2015; 12: 937-942.

165. van der Heijden A.C., Borleffs C.J., Buiten M.S. et al. The clinical course of patients with implantable defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm 2015; 12: 1169-1176.

166. Connolly S.J., Gent M., Roberts R.S. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.

167. Kuck K.H., Cappato R., Siebels J., Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 182: 748-754.

168. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N EngIJ Med 1997; 337: 1576-1583.

169. Connolly S.J., Hallstrom A.P., Cappato R. et al. Metaanalysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.

170. CASCADE Investigators. Randomized antiarrhyth mic drug therapy in survivors of cardiac arrest (the CASCADE Study). AmJ Cardio11993; 72: 280- 287.

171. Connolly S.J., Dorian P., Roberts R.S. et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295: 165 - 171.

172. Weiss R., Knight B.P., Gold M.R. et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128: 944-953.

173. Lambiase P.D., Barr C., Theuns D.A. et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 2014; 35: 1657-1665.

174. Bardy G.H., Smith W.M., Hood M.A. et al. An entirely subcutaneous implantable cardioverter-defibrillator. N EnglJ Meal 2010; 363: 36-44.

175. Jarman J.W., Lascelles K., Wong T. et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J 2012; 33: 1351-1359.

176. Dabiri Abkenari L., Theuns D.A., Valk S.D. et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 2011; 108: 737-744.

177. Olde Nordkamp L.R., Dabiri Abkenari L. et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.J Am Coil Cardiol 2012; 60: 1933-1939.

178. Aydin A., Hartel F., Schluter M. et al. Shock efficacy of subcutaneous implantable cardioverterdefibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol 2012; 5: 913-919.

179. Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace 2013; 15: 1158-1165.

180. Kobe J., Reinke F., Meyer C. et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013; 18: 29-36.

181. Burke M.C., Gold M.R., Knight B.P. et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry.J Am Coil Cardiol 2015; 65: 1605-1615.

182. Adler A., Halkin A., Viskin S. Wearable cardioverter-defibrillators. Circulation 2013; 127: 854- 860.

183. Auricchio A., Klein H., Geller C.J. et al. Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardio11998; 81: 125 3-1256.

184. Chung M.K., Szymkiewicz S.J., Shao M. et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coil Cardiol 2010; 56: 194-203.

185. Epstein A.E., Abraham W.T., Bianco N.R. et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infaretion. J Am Coil Cardio12013; 62: 2000-2007.

186. Klein H.U., Goldenberg I., Moss A.J. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J 2013; 34: 2230-2242.

187. Kao A.C., Krause S.W., Handa R. et al. Wearable defibrillator use In heart Failure (WIF) Investigators. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord 2012; 12: 123.

188. Hallstrom A.P., Omato J.P., Weisfeldt M. et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N EnglJ Med 2004; 351: 637-646.

189. Capucci A., Aschieri D., Piepoli M.F. et al. Tripling survival from sudden cardiac arrest via early defibrillation without traditional education in cardiopulmonary resuscitation. Circulation 2002; 106: 1065-1070.

190. de Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I. et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500-1505.

191. Moriwaki Y., Tahara Y., Iwashita M. et al. Risky locations for out-of-hospital cardiopulmonary arrest in a typical urban city.J Emerg Trauma Shock 2014; 7: 285-294.

192. Bardy G.H., Lee K.L., Mark D.B. et al. Rationale and design of the Home Automatic External defibrillator Trial (HAT). Am Heart J 2008; 155: 445-454.

193. Weisfeldt M.L., Sitlani C.M., Ornato J.P. et al. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million.J Am Coil Cardiol 2010; 55: 1713-1720.

194. Zafari A.M., Zarter S.K., Heggen V. et al. A program encouraging early defibrillation results in improved inhospital resuscitation efficacy.J Am Coil Cardiol 2004; 44: 846-852.

195. Nolan J.P., Hazinski M.F., Billi J.E. et al. Part 1: Executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Resuscitation 2010; 81 (Suppl 1): el-25.

196. Griffith M.J., Garratt C.J., Rowland E. et al. Effects of intravenous adenosine on verapamil-sensitive “idiopathic” ventricular tachycardia. Am J Cardiol 1994; 73: 759-764.

197. Carbucicchio C., Santamaria M., Trevisi N. et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117: 462-469.

198. Calkins H., Epstein A., Packer D. et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coil Cardiol 2000; 35: 1905-1914.

199. Stevenson W.G., Wilber D.J., Natale A. et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008; 118: 2773-2782.

200. Tanner H., Hindricks G., Volkmer M. et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 2.1: 47- 53.

201. Reddy V.Y., Reynolds M.R., Neuzil P. et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N EnglJ Med 2007; 357: 2657-2665.

202. Kuck K.H., Schaumann A., Eckardt L. et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375: 31-40.

203. Poole J.E., Johnson G.W., Hellkamp A.S. et al. Prognostic importance of defibrillator shocks in patients with heart failure. N EnglJ Med 2008; 359: 1009-1017.

204. Kamphuis H.C., de Leeuw J.R., Derksen R. et al. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace 2003; 5: 381-389.

205. de Bakker J.M., van Capelle F.J., Janse M.J. et al. Slow conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation 1993; 88: 915 -926.

206. de Chillou C., Lacroix D., Klug D., Magnin-Poul[ I., Marquie C., Messier M., Andronache M., Kouakam C., Sadoul N., Chen J., Allot E., Kacet S. Isthmus characteristics of reentrant ventricular tachycardia after myocardial infarction. Circulation 2002; 105: 726-731.

207. Littmann L., Svenson R.H., Gallagher J.J. et al. Functional role of the epicardium in postinfarction ventricular tachycardia. Observations derived from computerized epi-cardial activation mapping, entrainment, and epicardia[ laser photoablation. Circulation 1991; 83: 1577-1591.

208. Berruezo A., Mont L., Nava S., Chueca E. et al. Electrocardiographic recognition of the epicardial origin of ventricular tachycardias. Circulation 2004; 109: 1842-1847.

209. Daniels D.V., Lu Y.Y., Morton J.B., Santucci P.A. et al. Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiologi-cal characteristics, catheter ablation, and identification from the 12-1ead electrocardiogram. Circulation 2006; I 13: 1659-1666.

210. Bazan V., Gerstenfeld E.P., Garcia F.C. et al. Site-specific twelve-lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction. Heart Rhythm 2007; 4: 1403-1410.

211. Valles E., Bazan V., Marchlinski F.E. ECG criteria to identify epicardiaL ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol 2010; 3: 63-71.

212. Arenal A., Perez-David E., Avila P. et al. Noninvasive identification of epicardial ventricular tachycardia substrate by magnetic resonance-based signal intensity mapping. Heart Rhythm 2014; 11: 1456-1464.

213. Perez-David E., Arenal A., Rubio-Guivernau J.L. et al. Noninvasive identification of ventricular tachycardia-related conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: comparison of signal intensity scar mapping and endocardial voltage mapping. J Am Coil Cardiol 2011; 57: 184-194.

214. Bansch D., Bocker D., Brunn J. et al. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coil Cardiol 2000; 36: 566-573.

215. Haissaguerre M., Extramiana F., Hocini M. et al. Mapping and ablation of ventricular fibrillation associated with Long-QT and Brugada syndromes. Circulation 2003; 108: 925-928.

216. Berruezo A., Fernandez-Armenta J., Mont L. et al. Combined endocardiaL and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneLing technique. Grc Arrhythm Electrophysi ol 2012; 5: 111-121.

217. Marchlinski F.E., CaLlans D.J., Gottlieb C.D., Zado E. Linear abLation Lesions for control of unmappable ventricuLar tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000; 101: 1288-1296.

218. Jais P., Maury P., Khairy P. et al. Elimination of Local abnormal ventricular activities: a new endpoint for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012; 125: 2184-2196.

219. Di Blase L., Santangeli P., Burkhardt et al. Endoepicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coil Cardiol 2012; 60: 132-141.

220. Cano O., Hutchinson M., Lin D. et al. Electroanatomic substrate and ablation outcome for suspected epicardia[ ventricular tachycardia in left ventricular nonischemic cardiomyopathy. J Am Coil Cardiol 2009; S4: 799-808.

221. Bai R., Di Biase L., Shivkumar K. et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricu[ar dysplasia/ cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol 2011; 4: 478-485.

222. Dinov B., Fiedler L., Schonbauer R. et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014; 129: 728-736.

223. Kojodjojo P., Tokuda M., Bohnen M. et al. Electrocardiographic left ventricular scar burden predicts clinical outcomes following infarct-related ventricular tachycardia ablation. Heart Rhythm 2013; 10: 1119-1124.

224. Della Bella P., Baratto F., Tsiachris D. et al. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation 2013; 127: 1359-1368.

225. Peichl P., Wichterle D., Pavlu L. et al. Complications of catheter ablation of ventricular tachycardia: a single-center experience. Circ Arrhythm Electrophysiol 2014; 7: 684-690.

226. Mukaddirov M., Demaria R.G., Perrault L.P. et al. Reconstructive surgery of postinfarction left ventricular aneurysms: techniques and unsolved problems. Eur J Cardio-thorac Surg 2008; 34: 256-261.

227. Sartipy U., Albage A., Insulander P., Lindblom D. Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: the Karolinska approach. J Interv Card Electrophysiol 2007; 19: 171 - 178.

228. Moran J.M., Kehoe R.F., Loeb J.M. et al. Extended endocardial resection for the treatment of ventricular tachycardia and ventricular fibrillation. Ann Thorac Surg 1982; 34: 538-552.

229. O’Neill J.O., Starling R.C., Khaykin Y. et al. Residual high incidence ofventricular arrhythmias after left ventricular reconstructive surgery. J Thorac Cardiovasc Surg 2005; 130: 1250-1256.

230. Rastegar H., Link M.S., Foote C.B. et al. Perioperative and long-term results with mapping-guided subendocardial resection and left ventricular endoaneu rysmorrhaphy. Circulation 1996; 94: 1041 - 1048.

231. Page P.L., Cardinal R., Shenasa M., et al. Surgical treatment of ventricular tachycardia. Regional cryoabla-tion guided by computerized epicardial and endocardial mapping. Circulation 1989; 80: 1124-134.

232. Josephson M.E., Harken A.H., Horowitz L.N. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation 1979; 60: 1430-1439.

233. Krishnan S.C., Josephson M.E. Surgery for postinfarction ventricular tachycardia: is it obsolete? Pacing Clin Electrophysiol 2000; 23: 1295-1301.

234. Iwa T., Misaki T., Kawasuji M. et al. Long-term results of surgery for non-ischemic ventricular tachycardia. EurJ Cardiothorac Surg 1991; 5: 191-197.

235. Karamlou T., Silber I., Lao R. et al.Outcomes after late reoperation in patients with repaired tetralogy of Fallot: the impact of arrhythmia and arrhythmia surgery. Ann Thorac Surg 2006; 81: 1786-1793.

236. Tilz R.R., Makimoto H., Lin T. et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardiasfeasibility and clinical outcome. Europace 2014; 16: 1040-1052.

237. Schron E.B., Exner D.V., Yao Q. et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105: 589-594.

238. Irvine J., Dorian P., Baker B. et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002; 144: 282-289.

239. Koopman H.M., Vrijmoet-Wiersma C.M., Langius J.N. et al.Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter defibrillator. Pediatr Cardiol 2012; 33: 569-575.

240. Berg S.K., Higgins M., ReiUy C.M. et al. Sleep quality and sleepiness in persons with implantable cardioverter defibrillators: outcome from a clinical randomized longitudinal trial. Pacing Clin Electrophysiol 2012; 35: 431-443.

241. Vazquez L.D., Kuhl E.A., Shea J.B. et al. Age-specific differences in women with implantable cardioverter defibrillators: an international multi center study. Pacing Clin Electrophysiol 2008; 31: 1528-1534.

242. Magyar-Russell G., Thombs B.D., Cai J.X. et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 2011; 71: 223-231.

243. Braunschweig F., Boriani G., Bauer A. et al. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. Europace 2010; 12: 1673 - 1690.

244. Hoogwegt M.T., Kupper N., Theuns D.A. et al. Undertreatment of anxiety and depression in patients with an implantable cardioverter-defibrillator: impact on health status. Health Psychol 2012; 31: 745-753.

245. Lang S., Becker R., Wilke S. et al. Anxiety disorders in patients with implantable cardioverter defibrillators: frequency, course, predictors, and patients’ requests for treatment. Pacing Clin Electrophysiol 2014; 37: 35-47.

246. Kapa S., Rotondi-Trevisan D., Ilariano Z. et al. Psychopathology in patients with ICDs over time: results of a prospective study. Pacing Clin Electrophysiol 2010; 33: 198-208.

247. Morken I.M., Bru E,. Norekval T.M. et al. Perceived support from healthcare professionals, shock anxiety and post-traumatic stress in implantable cardioverter defibrillator recipients.J Clin Nurs 2014; 23: 450-460.

248. Versteeg H., Theuns D.A., Erdman R.A. et al. Posttraumatic stress in implantable cardioverter defibrillator patients: the role of preimplantation distress and shocks. IntJ Cardiol 2011; 146: 438-439.

249. Morken I.M., Isaksen K., Karlsen B. et al. Shock anxiety among implantable cardioverter defibrillator recipients with recent tachyarrhythmia. Pacing Clin Electrophysiol 2012; 35: 1369-1376.

250. Pedersen S.S., van den Broek K.C., Erdman R.A. et al. Preimplantation implantable cardioverter defibrillator concerns and type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace 2010; 12: 1446-1452.

251. Mastenbroek M.H., Versteeg H., Jordaens L., et al. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort. Psychosom Meal 2014; 76: 58-65.

252. Dunbar S.B., Dougherty C.M., Sears S.F. et al. Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement from the American Heart Association. Circulation 2012; 126: 2146- 2172.

253. Vijgen J., Botto G., Carom J. et al.Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 2009; 11: 1097-1107.

254. Johansson I., Stromberg A. Experiences of driving and driving restrictions in recipients with an implantable cardioverter defibrillator-the patient perspective. J Cardiovasc Nuts 2010; 25: E1 - El0.

255. Steinke E.E., Gill-Hopple K., Valdez D., Wooster M. Sexual concerns and educational needs after an implantable cardioverter defibrillator. Heart Lung 2005; 34: 299-308.

256. Steinke E.E., Jaarsma T., Barnason S.A. et al. Sexual counselling for individuals with cardiovascular disease and their partners: a consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). Eur Heart J 2013; 34: 3217-3235.

257. Zeigler V.L., Nelms T. Almost normal experiences of adolescents with implantable cardioverter defibrillators. J Spec Pediatr Nurs 2009; 14: 142-151.

258. Steg P.G., Cambou J.P., Goldstein P. et al. Bypassing the emergency room reduces delays and mortatity in ST etevation myocardiat infarction: the USIC 2000 registry. Heart 2006; 92: 1378-1383.

259. Soholm H., Wachte U.K., Nietsen S.L. et al. Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. Resuscitation 2013; 84: 162-167.

260. Xiao G., Guo Q., Shu M. et al. Safety profite and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis. Emerg MedJ 2013; 30: 91-100.

261. Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombotytic treatment in acute myocardiat infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775.

262. Boersma E., Primary Coronary Angioptasty vs. Thrombolysis Group. Does time matter? A pooled anatysis of randomized clinicat trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardiat infarction patients. Eur Heart J 2006; 27: 779-788.

263. Keeley E.C., Boura J.A., Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-etevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367: 579-588.

264. Roffi M., Patrono C., Cotter J.P. et al. 2015 ESC Guidetines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Eur Heart J 2015. doi: 10.1093/eurheartj/ehv320.

265. Spaulding C.M., Joly L.M., Rosenberg A. et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N EngIJ Med 1997; 336: 1629-1633.

266. Dumas F., Cariou A., Manzo-Sitberman S. et al. Immediate percutaneous coronary intervention is associated with better survivat after out-of-hospitat cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010; 3: 200-207.

267. Bowers T.R., O’Neitt WW, Grines C. t al. Effect of reperfusion on biventricutar function and survivat after right ventricular infarction. N EngIJ Med 1998; 338: 933-940

268. Reddy Y.M., Chinitz L. Mansour I.et al. Percutaneous left ventricular assist devices in ventricutar tachycardia ablation: mutticenter experience. Circ Arrhythm Electro-physio12014; 7: 244- 250.

269. Lamhaut L., Jouffroy R., Sotdan I. et al. Safety and feasibitity of prehospitat extra corporeat tile support imptementation by non-surgeons for out-of-hospital refractory cardiac arrest. Resuscitation 2013; 84: 1525-1529.

270. Wang C.H., Chou N.K., Becker L.B. et al. Improved outcome of extracorporeat cardioputmonary resuscitation for out-of-hospital cardiac arrest-a comparison with that for extracorporeal rescue for in-hospitat cardiac arrest. Resuscitation 2014; 85: 1219-1224.

271. Piccini J.P., Hranitzky P.M., Kilaru R. et al. Relation of mortality to failure to prescribe beta btockers acutety in patients with sustained ventricular tachycardia and ventricutar fibriltation fottowing acute myocardiat infarction (from the VALsartan In Acute myocardial iNfarcTion triat [VALIANT] Registry). Am J Cardiol 2008; 102: 1427-1432.

272. Wotfe C.L., Nibley C., Bhandari A. et al.Polymorphous ventricutar tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543 - 1551.

273. Chatterjee S., Chaudhuri D., Vedanthan R. et al. Early intravenous beta-blockers in patients with acute coronary syndrome a meta-analysis of randomized triats. IntJ Cardiol 2013; 168: 915-921.

274. Bangalore S., Makani H., Radford M. et al. Clinical outcomes with beta-blockers for myocardiat infarction: a meta-anatysis of randomized trials. Am J Med 2014; 127: 939-953.

275. Enjoji Y., Mizobuchi I., Muranishi et al. Catheter ablation of fatal ventricutar tachyarrhythmias storm in acute coronary syndrome~role of Purkinje fiber networlc J Interv Card Elec~rophysiol 2009; 26: 207-215.

276. Frankel D.S., Mountantonakis S.E., Robinson M.R. et al. Ventricutar tachycardia abtation remains treatment of last resort in structurat heart disease: argument for eartier intervention.J Cardiovasc Electrophysiol 2011; 22: 1123 - 1128.

277. Peichl P., Cihak R., Kozeluhova M. et al. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease.J Interv Card Elec~rophysiol 2010; 27: 51-59.

278. Deneke T., Lemke B., Mugge A. et al. Catheter ablation of electrical storm. Expert Rev Cardiovasc Ther 2011; 9: 1051-1058.

279. Deneke T., Shin D.I., Lawo T. et al. Catheter ablation of electrical storm in a cotlaborative hospital network. Am J Cardiol 2011; 108: 233-239.

280. Gorenek B., Blomstrom-Lundqvist C. et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EH R.A., ACCA, and EAPCI task force. Europace 2014; 16: 1655-1673.

281. Shaw D.J., Davidson J.E., Smilde R.I. et al. Multidis-ciptinary team training to enhance family communication in the ICU. Crit Care Meal 2014; 42: 265-271.

282. Piccini J.P., Schulte P.J., Pieper K.S. et al. Antiarrhythmic drug therapy for sustained ventricutar arrhythmias compticating acute myocardial infarction. Crit Care Med 2011; 39: 78-83.

283. Huikuri H.V., CasteUanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-1482.

284. Hine L.K., Laird N., Hewitt P., Chalmers T.C. Meta-analytic evidence against prophylactic use of tidocaine in acute myocardial infarction. Arch Intern Meal 1989; 149: 2694-2698.

285. Steg P.G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.

286. Borne R.T., Varosy P.D., Masoudi F.A. Implantable cardioverter-defibrittator shocks: epidemiotogy, outcomes, and therapeutic approaches.JAMA Intern Med 2013; 173: 859-865.

287. Liang J.J., Hodge D.O., Mehta IRA et al. Outcomes in patients with sustained ventricutar tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate? Europace 2014; 16: 1759-1766.

288. Hohnloser S.H., Kuck K.H., Dorian P. et al. Connotly S.J., Investigators D. Prophylactic use of an implantabte cardioverter-defibrittator after acute myocardiat infarction. N EngIJ Med 2004; 351: 2481-2488.

289. Steinbeck G., Andresen D., Seidl K. et al. IRIS Investigators. Defibritlator implantation early after myocardial infarction. N EngIJ Med 2009; 361: 1427-1436.

290. Noc M., Fajadet J., Lassen et al. Invasive coronary treatment strategies for out-of-hospitat cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascutar Interventions (EAPCI)/Stent for Life (SFL) groups. Eurolntervention 2014; 10: 31-37.

291. Bougouin W., Marijon E., Puymirat E. et al. Incidence of sudden cardiac death after ventricutar fibriltation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J 2014; 35: 116-122.

292. Avezum A., Piegas L.S., Goldberg R.J. et al. Magnitude and prognosis associated with ventricutar arrhythmias in patients hospitalized with acute coronary syndromes (from the GRACE Registry). Am J Cardiol 2008; 102: 1577-1582.

293. Piccini J.P., White J.A., Mehta R.H. et al. Sustained ventricular tachycardia and ventricular fibritlation complicating non-ST-segment-elevation acute coronary syndromes. Circulation 2012; 126: 41-49.

294. Buxton A.E., Lee K.L., DiCarlo L. et al. Etectrophysi-ologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342: 1937-1945.

295. Buxton A.E., Lee K.L., Harley G.E. et al.Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the M USTT study. J Am Coil Cardiol 2007; 50: 1150-1157.

296. Gatzoutis K.A., Tsiachris D., Arsenos P. et al. Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. IntJ Cardiol 2014; 176: 1449-1451.

297. Exner D.V., Kavanagh K.M., Stawnych M.P. et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coil Cardiol 2007; 50: 2275-2284.

298. Malik M., Camm A.J., Janse M.J. et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (the European Myocardial Infarct Amiodarone Triat).J Am Coil Cardiol 2000; 35: 1263-1275.

299. Zaman S., Narayan A., Thiagatingam A. et al. Longterm arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction. Circulation 2014; 129: 848 - 854.

300. Soholm H., Lonborg J., Andersen M.J. et al. Repeated echocardiography after first ever ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention-is it necessary? Eur Heart J Acute Cardiovasc Care 2014 Oct 15. pii: 2048872614556000.

301. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascutarization on prognosis in patients with coronary artery disease and left ventricutar dysfunction: a meta-anatysis. J Am Coil Cardiol 2002; 39: 1151-1158.

302. St John Sutton M., Pfeffer M.A., Plappert T. et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89: 68-75.

303. Gatzoulis K.A., Tsiachris D., Arsenos P. et al. Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients with Preserved Ejection Fraction: PRESERVE-EF Study Design. Hellenic J Cardiol 2014; 55: 361-368.

304. Kelly P., Ruskin J.N., Vtahakes G.J. et al. Surgical coronary revascutarization in survivors of prehospital cardiac arrest: its effect on inducible ventricutar arrhythmias and long-term survivaLJ Am Coil Cardio11990; 15: 267-273.

305. van der Burg A.E., BaxJJ, Boersma E et al. Impact of viability, ischemia, scar tissue, and revascutarization on outcome after aborted sudden death. Circulation 2003; 108: 1954-1959.

306. Бокерия Л.А., Алекян Б.Г., Барбараш Л.С. и соавт. Показания к реваскуляризации миокарда. Российский cогласительный документ. - М.: НЦССХ им. А. Н. Бакулева РАМН, 2011. - 162 с.

307. Bax J.J., Visser F.C., Potdermans D. et al. Time course of functional recovery of stunned and hibernating segments after surgical revascutarization. Circulation 2001; 104: 1314-1318.

308. Funaro S., La Torre G., Madonna M. et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009; 30: 566-575.

309. Cairns J.A., Connotly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular prematu re depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675-682.

310. Julian D.G., Camm A.J., Frangin G. et al. Randomised trial of effect of amiodarone on mortality in patients with teft-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.

311. Solomon S.D., Wang D., Finn P. et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-2183.

312. Cleland J.G., Massie B.M., Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999; 1: 41-45.

313. Gradman A., Deedwania P., Cody R. et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Ceptopril-Digoxin Study Group. J Am Colt Cardio11989; 14: 564-570.

314. Szabo B.M., van Veldhuisen D.J., Crijns H.J. et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricutar dysfunction and heart failure. Eur Heart J 1994; 15: 928-933.

315. Dovat H.C., Nut DR, Grancetli H.O. et al. Nonsustained ventricutar tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESI-CAGEMA Investigators. Circulation 1996; 74: 3198-3203.

316. Teerlink J.R., Jalaluddin M., Anderson S. et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Mitrinone Survival Evaluation) Investigators. Circulation 2000; 101: 40-46.

317. Aljaroudi W.A., Refaat M.M., Habib R.H. et al. Genetic Risk Assessment of Defibrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate imptantabte cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). AmJ Cardiol 2015; 115: 924-931.

318. Pitt B., White H., Nicolau J., Martinez F. et al. Eplere-none reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricutar systolic dysfunction and heart faiture.J Am Coil Cardiol 2005; 46: 425-431.

319. Peck K.Y., Lim Y.Z., Hopper I., Krum H. Medical therapy versus implantable cardioverter-defibrittator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. IntJ Cardiol 2014; 173: 197-203.

320. Chatteijee S., Udetl J.A., Sardar P. et al. Comparable benefit of betablocker therapy in heart failu re across regions of the world: meta-analysis of randomized clinical trials. CanJ Cardiol 2014; 30: 898-903.

321. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Triats. JAMA 1995; 273: 1450-1456.

322. Kotecha D., Holmes J., Krum H. et al. Beta-Blockers in Heart Failure Collaborative Grou p. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-anatysis. Lancet 2014; 384: 2235-2243.

323. Kotecha D., Airman D.G., Manzano L., Flather M.D., Beta-Blockers in Heart Failure Collaborative Group. beta blockers in patients with heart failure and atrial fibrilration--authors’ reply. Lancet 2015; 385: 1618-1619.

324. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Atdactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.

325. Zannad F., McMurray J.J., Krum H. et al. Epterenone in patients with systolic heart failure and mild symptoms. N EngIJ Med 2011; 364: 11-21.

326. Bapoje S.R., Bahia A., Hokanson J.E. et al. Effects of mineratocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricutar systolic dysfunction: a meta-anatysis of randomized controlled trials. Circ Heart Fag 2013; 6: 166-173.

327. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiotogy, diagnosis, and treatment- Eur Heart J 2011; 32: 670-679.

328. Chan M.M., Lam C.S. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15: 604-613.

329. Bristow M.R., Saxon L.A., Boehmer J. et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-re-synchronization therapy with or without an imptantable defibrillator in advanced chronic heart failure. N EngIJ Med 2004; 350: 2140-2150.

330. Cleland J.G., Daubert J.C., Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.

331. van Veldhuisen D.J., Maass A.H., Priori S.G. et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. EurJ Heart Fail 2009; 11: 1143-1151.

332. Kadish A., Dyer A., Daubert J.P. et al. Defibrillators in Non-lschemic Cardiomyopathy Treatment Evaluation Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.

333. Desai A.S., Fang J.C., Maiset W.H., Baughman K.L. Imptantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-2879.

334. Kober L., Thune J.J., Nielsen J.C. et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH). N Engl J Med 2016; 375: 1221-1230.

335. Goldenberg I., Moss A.J., McNitt S. et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 1811 -1817.

336. Packer D.L., Prutkin J.M., Hettkamp A.S. et al. Impact of implantable cardioverter-defibritlator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009; 120: 2170-2176.

337. Bansch D., Antz M., Boczor S. et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-1458.

338. Strickberger S.A., Hummel J.D., Bartlett T.G. et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coil Cardiol 2003; 41: 1707-1712.

339. Frohlich G.M., HoLzmeisterJ., Hubler M. et al. Prophylactic imp[antab[e cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart 2013; 99: 1158-1165.

340. Sandner S.E., Wiese[thaler G., Zuckermann A. et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation 2001; 104: 1171-1176.

341. Zareba W., Klein H., Cygankiewicz I. et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 123: 1061-1072.

342. Birnie D.H., Ha A., Higginson L. et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013; 6: 1190-1198.

343. Nery P.B., Ha A.C., Keren A., Birnie D.H. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm 2011; 8: 1083-1087.

344. Sipahi I., Chou J.C., Hyden M. et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163: 260-267.

345. Bilchick K.C., Kamath S., DiMarco J.P., Stukenborg G]. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Grculation 2010; 122.: 2022-2030.

346. Tang A.S., Wells G.A., Talajic M. et al. Resynchroniza-tionDefibrillation forAmbulatoiy Heart Failure Trial (RAFT) Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N EngIJ Med 2010; 363: 2385-2395.

347. Sipahi I., Carrigan T.P., Rowland D.Y. et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011; 171: 1454-1462.

348. Moss A.J., Hall W.J., Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N EnglJ Med 2009; 361: 1329-1338.

349. Cleland J.G., Abraham W.T., Linde C. et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547-3556.

350. Linde C., Leclercq C., Rex S. et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUItisite STimulation in cardiomyopathy (MUSTIC) study.J Am Colt Cardiol 2002; 41}: 111 -118.

351. Doshi R.N., Daoud E.G., Fellows C. et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16: 1160-1165.

352. Ganesan A.N., Brooks A.G., Roberts-Thomson K.C. et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review.J Am CoIl Cardiol 2012; S?: 719-726.

353. Gasparini M., Leclercq C., Lunati M. et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1: 500-507.

354. Deyell M.W., Park K.M., Han Y. et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9: 1465 - 1472.

355. Barnan T.S., Lange D.C., IIg K.J. et al. Relationship between burden of premature ventricular complexes and [eft ventricular function. Heart Rhythm 2010; 7: 865-869.

356. Ban J.E., Park H.C., Park J.S. et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace 2013; lS: 735-741.

357. Maggioni A.P., Zuanetti G., Franzosi M.G. et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312-322.

358. Blanck Z., Dhala A., Deshpande S. et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993; 4: 253-262.

359. Caceres J., Jazayeri P1., PlcKinnie J. et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989; 79: 256-270.

360. Tchou P., Jazayeri M., Denker S. et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988; 78: 246-257.

361. Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 2.9: 270-276.

362. Taylor M.R., Carniel E., Mestroni L. Familial dilated cardiomyopathy. OrphanetJ Rare Dis 2006; 1: 27.

363. Towbin J.A., Lowe A.M., Colan S.D. et al. Incidence, causes, and outcomes of dilated cardiomyopathy in chil-dren.JAMA 2006; 2.96: 1867-1876.

364. Petretta M., Pirozzi F., Sasso L. et al. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol 2011; 108: 1171-1176.

365. Haas J., Frese K.S., Peil B. et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015; 36: 1123-1135.

366. Hershberger R.E., Lindenfeld J., Plestroni L. et al. Genetic evaluation of cardiomyopathy--a Heart Failu re Society of America practice guideline. J Card Fail 2009; 1 S: 83-97.

367. Proietti R., Essebag V., Beardsatl J. et al. Substrate-guided ablation of haemodynamicatly tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on tong-term outcome. Europace. 2015; 17: 461-467.

368. Kober L., Torp-Pedersen C., McMurray J.J. et al. Increased mortality after dronedarone therapy for severe heart failure. N EngIJ Med 2008; 358: 2678-2687.

369. Connolly S.J., Camm A.J., Hatperin J.L. et al. Droneda-rone in highrisk permanent atrial fibrillation. N EngI J Med 2011; 365: 2268-2276.

370. Castelli G., Fornaro A., Ciaccheri M. et al. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail 2013; 6: 913-921.

371. Alexander P.M., Daubeney P.E., Nugent A.W. et al. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy. Circulation 2013; 128: 2039-2046.

372. Kuruvilla S., Adenaw N., Katwat A.B. et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-anatysis. Circ Cardiovasc Imaging 2014; 7: 250-258.

373. Roden D.M. Drug-induced prolongation of the QT interval. N EngI J Med 2004; 350: 1013-1022.

374. Chamberlain.D.A., Jewitt D.E., Julian D.G. et al. Oral mexitetine in high-risk patients after myocardial infarction. Lancet 1980; 2: 1324-1327.

375. Elliott P.M., Gimeno J.R., Thaman Ret al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92: 785-791.

376. O’Mahony C., Jichi F., Pavlou M. et al. A novel clinicat risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35: 2010-2020.

377. Pelliccia A., Fagard R., Bjornstad H.H. et al. Recommendations for competitive sports participation in athletes with cardiovascutar disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabititation and Exercise Physiotogy and the Working Group of Myocardiat and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-1445.

378. O’Mahony C, Tome-Esteban M, Larnbiase PDet al. A validation study of the 2003 American Coltege of Cardiotogy / European Society of Cardiotogy and 2011 American Coltege of Cardiotogy Foundation / American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 2013; 99: 534-541.

379. O’Mahony C., Lambiase P.D., Quarta G. et al. The long-term survival and the risks and benefits of imptantabte cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012; 98: 116-125.

380. Elliott P.M., Sharma S., Varnava A. et al. Survival after cardiac arrest or sustained ventricutar tachycardia in patients with hypertrophic cardiomyopathy. J Am Coil Car-dio11999; 33: 1596-1601.

381. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy suc-cessfulty resuscitated after cardiac arrest. J Am Coil Cardiol 1989; 13: 1283-1288

382. Maron B.J., Spirito P., Shen W.K. et al. Piccininno M., Winters S.L., Santini M., Betocchi S., Arribas F., Sherrid M.V., Buja G., Semsarian C., Bruzzi P. Implantable cardioverter-defibriltators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA 2007; 298: 405-412

383. Syska P., Przybylski A., Chojnowska L. et al. Imptant-able cardioverter-defibritlator in patients with hypertrophic cardiornyopathy: efficacy and complications of the therapy in tong-term follow-up. J Cardiovasc Electrophysiol 2010; 21: 883 -889

384. Monserrat L., Eltiott P.M., Gimeno J Ret al. Nonsustained ventricutar tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.J Am Coil Cardiol 2003; 42: 873-879

385. Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Hotter etectrocardiogram in hypertrophic cardiomyopathy. J Am Coil Cardiol 2005; 45: 697-704

386. O’Hanlon R., Grasso A., Roughton M. et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2599-2605

387. Inada K., Seller J., Roberts-Thomson K.C. et al. Substrate characterization and catheter ablation for mono-morphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2011; 22: 41-48

388. Maron B.J., McKenna W.J., Danielson G.K. et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965 - 1991

389. Gersh B.J., Maron B.J., Bonow R.O. et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783-e831.

390. McKenna W.J., Oaktey C.M., Krikler D.M., Goodwin J.F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-416.

391. Melacini P., Maron B.J., Bobbo F. et al. Evidence that pharmacobgicat strategies tack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007; 93: 708-710.

392. Marcus F.I., McKenna W.J., Sherri U.D. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy / dysplasia: proposed modification of the task force criteria. Eur Heart J 2010; 31: 806- 814.

393. Basso C., Corrado D., Marcus F.I. et al. Arrhythmogenic right ventricutar cardiomyopathy. Lancet 2009; 373: 1289-1300.

394. Sen-Chowdhry S., Syrris P., Prasad S.K. et al. Leftdominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity.J Am Coil Cardiol 2008; 52: 2175-2187.

395. Basso C., Corrado D., Thiene G. Cardiovascular causes of sudden death in young individuals including athtetes. Cardiol Rev 1999; 7: 127-135.

396. Tabib A., Loire R., Chalabreysse L. et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricutar cardiomyopathy and/or dysplasia. Circulation 2003; 108: 3000-3005.

397. Schinkel A.F. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol 2013; 6: 562-568.

398. Ruwald A.C., Marcus F., Estes N.A. 3rd et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2015; 36: 1735-43.

399. Corrado D., Leoni L., Link M.S. et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108: 3084-3091.

400. Marcus G.M., Glidden D.V., Polonsky B. et al. Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coil Cardiol 2009; S4: 609-615.

401. Wichter T., Borggrefe M., Haverkamp W. et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992; 86: 29-37.

402. Philips B., Madhavan S., James C., et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 2012; S: 499-505.

403. Dalal D., Jain R., Tandri H. et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomy-opathy.J Am Coil Cardiol 2007; S0: 432-440.

404. Dalal D., Molin L.H., Piccini J. et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113: 1641-1649.

405. Wichter T., Paul M., Wollmann C. et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Cir-culatJon 2004; 107: 1503-1508.

406. Nava A., Bauce B., Basso C. et al. Clinical profile and long-term followup of 37 families with arrhythmogenic right ventricular cardiomyopathy.J Am Coll Cardiol 2000; 36: 2226-2233.

407. Nasir K., Bomma C., Tandri H. et al. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation 2004; 110: 1527-1534.

408. Hamid M.S., Norman M., Quraishi A. et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002; 40: 1445-1450.

409. Sen-Chowdhry S., Syrris P., Ward D. et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007; 115: 1710-1720.

410. Hoffmayer K.S., Machado O.N., Marcus G.M. et al. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Colt Cardiol 2011; A8: 831-838.

411. Link M.S., Laidlaw D., Polonsky et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment.J Am Coil Cardiol 2014; 64: 119-125.

412. Ouyang F., Fotuhi P., Goya M., et al. Ventricular tachycardia around the tricuspid annulus in right ventricu[ar dysplasia. Circulation 2001; 103: 913-914

413. Heidbuchel H., Hoogsteen J., Fagard R. et al. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. £ur Heart J 2003; 24: 1473-1480.

414. Corrado D., Calkins H., Link M.S. et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricu[ar fibrillation or sustained ventricu[ar tachycardia. Circulation 2010; 122: 1144-1152.

415. Peters S. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres.J Cardiovasc Med (Hagerstown) 2007; 8: 521-526.

416. Lemola K., Brunckhorst C., Helfenstein U. et al. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. Heart 2005; 91: 1167-1172.

417. Rigato I., Bauce B., Rampazzo A. et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal generelated arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013; 6: 533-542.

418. Kristen A.V., Dengler T.J., Hegenbart U. et al. Prophylactic implantation of cardioverterdefibrillator in patients with severe cardiac amy[oidosis and high risk for sudden cardiac death. Heart Rhythm 2008; S: 235-240.

419. Palladini G., Malamani G., Co F., Pistorio A. et al. Holter monitoring in AL amyloidosis: prognostic implications. Paring Ciin Electrophysiol 2001; 24: 1228-1233.

420. Dubrey S.W., Bilazarian S., LaVaUey M. et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 1997; 134: 994-1001.

421. Reisinger J., Dubrey S.W., Lava[ley M. et al. Electro-physiologic abnormalities in AL (primary) amyloidosis with cardiac invo[vement.J Am Coil Cardiol 1997; 30: 1046-1051.

422. Ammash N.M., Seward J.B., Bailey K.R. et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101: 2490-2496.

423. Dubrey S.W. Amyloid heart disease: a brief review of treatment options. Postgrad Med J 2012; 88: 700-705.

424. Ruberg F.L., Berk J.L. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 12.6: 1286-1300.

425. Jaccard A., Comenzo R.L. Kaski, Hari P. et al. Efficacy of bortezomib, cyclophosphamide and dexametha-sone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014; 99: 1479-1485.

426. Falk R.H., Rubinow A., Cohen A.S. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardio-graphic abnormalities.J Am Coil Cardio11984; 3: 107-113.

427. Plaskatia S.A., Decker J.A., Spinner J.A. et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012; 33: 141-149.

428. Rivenes S.M., Keamey D.L., Smith E.O. et al. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000; 102.: 876-882.

429. Lipshultz S.E., Orav E.J., Wilkinson J.D. et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013; 382.: 1889-1897.

430. Webber S.A., Lipshultz S.E., Sleeper L.A. et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circula’don 2012; 12.6: 1237-1244.

431. Kaski J.P., Syrris P., Butch P. et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart 2008; 94: 1478 - 1484.

432. Bhatia N.L., Tajik A.J., Wilansky S. et al. Isolated noncompaction of the left ventricular myocardium in adults: a systematic overview.J Card Fail 2011; 17: 771-778.

433. Oechslin E., Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? Eur Heart J 2011; 32.: 1446-1456.

434. Lofiego C., Biagini E., Pasquale F. et al. Wide spectrum of presentation and variable outcomes of isolated left ventricular noncompaction. Heart 2007; 93: 65-71.

435. Murphy R.T., Thaman R., Btanes J.G. et al. Natural history and famitiat characteristics of isotated left ventricular non-compaction. Eur Heart J 2005; 26: 187-192.

436. Muratore C.A., Batista Sa L.A., Chiate P.A. et al. Imptantabte cardioverter defibritlators and Chagas’ disease: resutts of the ICD Registry Latin America. Europace 2009; 11: 164-168.

437. Martinelti L., de Siqueira S.F., Sternick E.B. et al. Longterm follow-up of implantable cardioverter-defibritlator for secondary prevention in Chagas’ heart disease. AmJ Cardiol 2012; 110: 1040-1045.

438. Cardinalti-Neto A., Bestetti R.B., CordeiroJ.A , Rodrigues V.C. Predictors of air-cause mortality for patients with chronic Chagas’ heart disease receiving imptantabte cardioverter defibriltator therapy.J Cardiovasc Electrophysiol 2007; ’18: 1236-1240.

439. Barbosa M.P., da Costa Rocha 1’40, de Oliveira A.B. et al. Efficacy and safety of implantabte cardioverter-de-fibritlators in patients with Chagas disease. Europace 2013; 15: 957-962.

440. Gali W.L., Sarabanda A.V., Baggio J.M. et al. Implantable cardioverter-defibdltators for treatment of sustained ventricutar arrhythmias in patients with Chagas’ heart disease: comparison with a controt group treated with amio-darone atone. Europace 2014; 16: 674-680.

441. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the tong QT syndrome. An update. Circulation 1993; 88: 782-784.

442. Schwartz P., Crotti L. QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation. 2011; 124: 2181-2184.

443. Moss A.J., Schwartz P.J., Crampton R.S. et al. The long QT syndrome. Prospective tongitudinal study of 328 families. Circulation 1991; 84: 1136-1144.

444. Nguyen H.L., Pieper G.H., Wilders R. Andersen-Tawil syndrome: clinical and molecular aspects. IntJ Cardiol 2013; 170: 1-16.

445. Schwartz P.J., Priori S.G., Spazzolini C. et al. Genotype-phenotype correlation in the Iong-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.

446. Priori S.G., Napolitano C., Schwartz P.J. et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292: 1341 - 1344.

447. Moss A.J., Zareba W., Hall W.J. et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616-623.

448. Zareba W., Moss A.J., Daubert J.P. et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients.J Cardiovasc Electrophysiol 2003; ’14: 337-341.

449. Schwartz P.J., Spazzolini C., Priori S.G. et al. Who are the Iong-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Imp[antable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010; 122: 1272-1282.

450. Jons C., Moss A.J., Goldenberg I. et al. Risk of fatal arrhythmic events in long QT syndrome patients after syn-cope.J Am Coll Cardiol 2010; 55: 783 -788.

451. Ильдарова Р.А., Школьникова М.А., Березницкая В.В., Термосесов С.А. Efficacy of ICD therapy in highrisk children with Long QT syndrome. European Heart Journal 2012; Vol. 33 (Abstract Supplement) - P. 4102.

452. Schwartz P.J., Priori S.G., Cerrone M. et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109: 1826-1833.

453. Schwartz P.J., Priori S.G., Locati E.H. et al. Long QT syndrome patients with mutations of the SCNSA and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for genespecific therapy. Circulation 1995; 92: 3381-3386.

454. Moss A.J., Windle J.R., Hall W.J. et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial Ann Noninvasive Electrocardiol 2005; 10: 59-66.

455. Moss A.J., Zareba W., Schwar’z K.Q. et al. Ranolazine shortens repo[arization in patients with sustained inward sodium current due to type-3 Iong-QT syndrome. J Cardiovasc Electrophysiol 2008; ’19: 1289-1293.

456. Макаров Л.М. Холтеровское мониторирование. 4е издание. ИД М.: Медпрактика - М.; 2016, (в печати).

457. Liu J.F., Jons C., Moss A.J. et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am CoU Cardiol 2011; 57: 941-950.

458. Seth R., Moss A.J., McNitt S. et al.Long QT syndrome and pregnancy.J Am Coil Cardiol 2007; 49: 1092-1098.

459. Goldenberg I., Horr S., Moss A.J. et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coil Cardiol 2011; 57: 51-59.

460. Gaita F., Giustetto C., Bianchi F. et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003; 108: 965-970.

461. Gaita F., Giustetto C., Bianchi F. et al. Short QT syndrome: pharmacological treatment. J Am COIl Cardiol 2004; 43: 1494-1499.

462. Fowler S.J., Priori S.G. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009; 24: 74-81.

463. Gehi A.K., Duong T.D., Metz L.D., Gomes J.A., Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis.J Cardiovasc Electrophysiol 2006; 17: 577-583.

464. Priori S.G., Napolitano C., Gasparini M. et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; ’105: 1342-1347.

465. Fauchier L., Isorni M.A., Clement N. et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: an updated meta-analysis of worldwide published data. IntJ Cardiol 2013; 168: 3027-3029.

466. Maury P., Hocini M., Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005; 5: 25-34.

467. Marquez M.F., Bonny A., Hemandez-Castillo E. et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012; 9: 1995-2000.

468. Nademanee K., Veerakul G., Chandanamattha P. et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123: 1270-1279.

469. Priori S., Gasparini M., Napolitano C. et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.J Am Coil Cardio12012; 59: 37-45.

470. Coumel P. Catecholamine-induced severe ventricular arrhythmias with AdamsStokes syndrome in children: a report of four cases. Br Heart J 1978; 40: 28-37.

471. Макаров Л.М., Курылева Т.А., Чупрова С.Н. Укорочение интервала PR, брадикардия и полиморфная желудочковая тахикардия - клинико-электрокардиографический синдром с высоким риском внезапной смерти у детей. Кардиология. - 2003. - № 7. - С. 34-37.

472. Makarov L., Kyrileva T., Chuprova S. Short PR interval, high circadian index and bradycardia - pattern with high risk of syncope and sudden death in children with catecholaminergic ventricular tachycardia. Europ Heart J 2004; 25: 222, p.23 (Supl.)

473. Makarov L., Kyrileva T., Komoliatova T., Chuprova S. New ECG pattern in young patients with polymorphic catecholaminergic ventricular tachycardia. JACC 2007; March 6, 2007 Vol. 49, N 9 (Suppl A). 916-242

474. Priori S.G., Napolitano C., Memmi M. et al. Clinical and molecular characterization of patients with catechol-aminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74.

475. Marjamaa A., Hiippata A., Arrhenius B. et al.Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012; 23: 194-199.

476. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. // Heart. - 2003 (89). - P. 66 -70

477. Leenhardt A., Lucet V., Denjoy I. et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year foUow-up of 21 patients. Circulation 1995; 71: 1512-1519.

478. Hayashi M., Denjoy I., Extramiana F. et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricutar tachycardia. Circulation 2009; 119: 2426-2434.

479. van der Werf C., Nederend I., Hofman N. et al.Familial evatuation in catechotaminergic polymorphic ventricutar tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012; 5: 748-756.

480. Watanabe H., Chopra N., Laver D. et al. Ftecainide prevents catechotaminergic potymorphic ventricutar tachycardia in mice and humans. Nat Meal 2009; 15: 380-383.

481. Otde Nordkamp L.R., Driessen A.H., Odero A., et al. Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Neth Heart J 2014; 22: 160-166.

482. Hofferberth S.C., Cecchin F., Loberman D., Fynn-Thompson F. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricutar arrhythmias. J Thorac Cardiovasc Surg 2014; 147: 404-409.

483. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. // Circulation. 1995 (91). - P. 1512-151913.

484. Watanabe H., Chopra N., Laver D., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. // Nat Med. - 2009 (15). - P. 380-383.

485. Березницкая В.В., Термосесов С.А., Школьникова М.А. Prognostic importance of supraventricular arrhythmia in children with chatecholaminergic ventricular tachycardia // European Heart Journal 2011; Vol.32 (Abstract Supplement): 1112, Abstracts ESC Congress 2011, 27-31 Aug 2011, Paris, France. - P5863

486. Roses-Noguer F., Jarman J.W., Clague J.R., Tilt J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2014; 11: 58-66.

487. Haissaguerre M., Derval N., Sachet F. et al. Sudden cardiac arrest associated with early repotarization. N Engl J Med 2008; 358: 2016-2023.

488. Rosso R., Kogan E., Belhassen B. et al. J-point elevation in survivors of primary ventricutar fibrillation and matched control subjects: incidence and clinical significance.J Am Coil Cardiol 2008; 52: 1231-1238.

489. Paul T., Marchat C., Garson A. Jr. Ventricular couplets in the young: prognosis related to underlying substrate. Am Heart J 1990; 119: 577-582.

490. Beaufort-Krot G.C., Dijkstra S.S., Bink-Boelkens M.T. Natural history of ventricutar premature contractions in children with a structurally normal heart: does origin matter? Europace 2008; 10: 998-1003.

491. Pfammatter J.P., Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coil Cardio11999; 33: 2067-2072.

492. Wang S., Zhu W., Hamilton R.M. et al. Diagnosis specific characteristics of ventricutar tachycardia in children with structurally normat hearts. Heart Rhythm 2010; 7: 1725-1731.

493. Collins K.K., Schaffer M.S., Liberman L. et al. Fascicular and nonfascicular left ventricular tachycaralias in the young: an international multicenter study.J Cardiovasc Electrophysiol 2013; 2.4: 640-648.

494. Schneider H.E., Kriebel T., Jung K. et al. Catheter ablation of idiopathic left and right ventricutar tachycardias in the pediatric population using noncontact mapping. Heart Rhythm 2010; 7: 731-739.

495. Blaufox A.D., Felix G.L., Saul J.P. Radiofrequency catheter ablation in infants №18 months old: when is it done and how do they fare?: short-term data from the pediatric ablation registry. Circulation 2001; 104: 2803-2808.

496. Lapage M.J., Bradley D.J., Dick M 2nd. Verapamil in infants: an exaggerated fear? Pediatr Cardiol 2013; 34: 1532-1534.

497. Nagashima M., Matsushima M., Ogawa A. et al. Cardiac arrhythmias in healthy children revealed by 24-hour ambulatory ECG monitoring. Pediatr Cardiol 1987; 8: 103-108.

498. Southatl D.P., Richards J., Mitchell P. et al. Study of cardiac rhythm in healthy newborn infants. Br Heart J 1980; 43: 14-20.

499. Jacobsen J.R., Garson A J.R., Gillette P.C., McNamara D.G. Premature ventricular contractions in normal chitdren. J Pediatr 1978; 92.: 36-38.

500. Tsuji A., Nagashima M., Hasegawa S. et al. Long-term follow-up of idiopathic ventricular arrhythmias in otherwise normal children.Jpn CircJ 1995; 57: 654-662.

501. Van Hare G.F., Stanger P. Ventricular tachycardia and accelerated ventricutar rhythm presenting in the first month of life. AmJ Cardio11991; 67: 42-45.

502. Iwamoto L., Niimura I., Shibata T. et al. S. Long-term course and clinical characteristics of ventricutar tachycardia detected in children by school-based heart disease screening. CircJ 2005; 69: 273-276.

503. Roggen A., Pavlovic M., Pfammatter J.P. Frequency of spontaneous ventricular tachycardia in a pediatric population. AmJ Cardiol 2008; 101: 852-854.

504. Garson A J.R., Smith RT J.R., Moak J.P. et al. Incessant ventricutar tachycardia in infants: myocardial hamartomas and surgical cure.J Am Coil Cardio11987; 18: 619-626.

505. Paul T., Bokenkamp R., Mahnert B., Trappe H.J. Coronary artery involvement early and late after radiofrequency current application in young pigs. Am Heart J 1997; 133: 436 -440.

506. Khairy P., Guerra P.G., Rivard L. et al. Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study. Circ Ar-rhythm Electrophysiol 2011; 4: 211 -217.

507. Saut J.P., Hulse J.E., Papagiannis J. et al. Late enlargement of radiofrequency lesions in infant lambs. Implications for ablation procedures in small children. Circulation 1994; 98: 492-499.

508. Khairy P., Harris L., Landzberg M.J. et al. Implant.able cardioverter-defibritlators in tetralogy of Fatlot. Circulation 2008; 117: 363-370.

509. Khairy P., Harris L., Landzberg M.J. et al. et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol 2008; 1: 250-257.

510. Berut C.I., Van Hare G.F., Kertesz N.J. et al. Results of a multicenter retrospective imptantabte cardioverter-defibrillator registry of pediatric and congenital heart disease patients.J Am Coil Cardiol 2008; 51: 1685-1691.

511. Koyak Z., de Groot J.R., Van Gelder I.C. et al. Imptantabte cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Ar-rhythm Electrophysiol 2012; 5: 101 - 110.

512. Zeppenfetd K., Schalij M.J., Bartetings M.M. et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: etectroanatomic identification of the critical right ventricutar isthmus. Circulation 2007; 116: 2241-2252.

513. Gatlego P., Gonzalez A.E., Sanchez-Recatde A. et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol 2012; 110: 109-117.

514. Ghai A., Silversides C., Harris L. et al. Left ventricutar dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coil Cardiol 2002; 48: 1675 - 1680.

515. Gatzoulis H.A., Bataji S., Webber S.A. et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fattot: a multicentre study. Lancet 2000; 356: 975-981.

516. Khairy P., Landzberg M.J., Gatzoulis M.A. et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004; 189: 1994-2000.

517. Koyak Z., Harris L., de Groot J.R. et al. Sudden cardiac death in adult congenital heart disease. Circulation 2012; 12.6: 1944-1954.

518. Kammeraad J.A., van Deur-zen C.H., Sreeram N. et al. Predictors of sudden cardiac death after Mustard or Sen-ning repair for transposition of the great arteries. J Am Coil Cardiol 2004; 44: 1095 - 1102.

519. van tier Linde D., Konings E.E., Stager M.A. et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241-2247.

520. Marelli A.J., Mackie A.S., Ionescu-lttu R., Rahme E., Pitote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-172.

521. Sitka M.J., Hardy B.G., Menashe V.D., Morris C.D. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coil Cardio11998; 32.: 245 -251.

522. Oechstin E.N., Harrison D.A., Connetly M.S. et al. Mode of death in adults with congenital heart disease. Am J Cardiol 2000; 86: 1111-1116.

523. Nieminen H.P., Jokinen E.V., Sairanen H.I. Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coil Cardiol 2007; 50: 1263-1271.

524. Murphy J.G., Gersh B.J., Mair D.D. et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N EngIJ Med 1993; 32.9: 593-599.

525. Moons P., Gewillig M., Stuysmans T. et al. Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium. Heart 2004; 98: 307- 313.

526. Brown D.W., Dipitato A.E., Chong E.C. et al. Sudden unexpected death after balloon valvuloptasty for congenital aortic stenosis.J Am CoIl Cardiol 2010; 56: 1939-1946.

527. Khairy P., Fernandes S.M., Mayer J.E. et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008; 117: 85-92.

528. Heersche J.H., Blom N.A., van de Heuvel F. et al. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands. Pacing Ciin Electrophysiol 2010; 33: 179 - 185.

529. Silka M.J., Kron J., Dunnigan A., Dick M. 2nd. Sudden cardiac death and the use of implantable cardio-verter-defibrillators in pediatric patients. The Pediatric Electrophysio[ogy Society. Circulation 1993; 87: 800-807.

530. Etheridge S.P., Sanatani S., Cohen M.I. et al. Long QT syndrome in children in the era of implantable defibrilla-tors.JAm Coil Cardio12007; 50: 1335-1340.

531. Maron B.J., Spirito P., Ackerman M.J. et al. Prevention of sudden cardiac death with implantable cardioverter-defibrllators in children and adolescents with hypertrophic cardiomyopathy. J Am Coil Cardiol 2013; 61: 1527-1535.

532. Radbill A.E., Triedman J.K., Berul C.I. et al. System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients. Heart Rhythm 2010; 7: 193-198.

533. Burns K.M., Evans F., Kaltman J.R. Pediatric ICD utilization in the United States from 1997 to 2006. Heart Rhythm 2011; 8: 23-28.

534. Pahl E., Sleeper L.A., Canter C.E. et al. et al. Pediatric Cardiomyopathy Registry I. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012; 59: 607-615.

535. Dimas W., Denfield S.W., Friedman R.A. et al. Frequency of cardiac death in children with idiopathic dilated cardiomyopathy. AmJ Cardiol 2009; 104: 1574-1577.

536. Hamilton R.M., Dorian P., Gow RI~I, Williams W.G. Five-year experience with implantable defibrillators in children. AmJ Cardiol1996; 77: 524-526.

537. Chatrath R., Porter C.B., Ackerman M.J. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. Mayo Ciin Proc 2002; 99: 226-231.

538. Lawrence D., Van Bergen N., Law I.H. et al. Inappropriate ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult population.J Cardiovasc Electrophysiol 2009; 20: 287-290.

539. Celiker A., Olgun H., Karagoz T. et al. Midterm experience with implantable cardioverter-defibrillators in children and young adults. Europace 2010; 12: 1732-1738.

540. Shah M.J. Implantable cardioverter defibrillator-related complications in the pediatric population. Pacing Clin Electrophysiol 2009; 32(Supp[ 2): S71-S74.

541. Janson C.M., Patel A.R., Bonney W.J. et al. Implantable cardioverter-defibrillator lead failure in children and young adults: a matter of lead diameter or lead design?JAm Coil Cardiol 2014; 63: 133-140.

542. Atallah J., Erickson C.C., Cecchin F. et al. Pediatric and Congenital Electrophysiology Society (PACES). Multi-institutional study of implantable defibrillator lead performance in children and young adults: results of the Pediatric Lead Extractability and Survival Evaluation (PLEASE) study. Circulation 2013; 127: 2393-2402.

543. Janousek J., Gebauer R.A., AbduI-Khaliq H. et al. Working Group for Cardiac Dysrhythmias and Electrophysiology of the Association for European Paediatric Cardiology. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009; 95: 1165-1171.

544. van der Hulst A.E., Delgado V., Biota N.A. et al. Cardiac resynchronization therapy in paediatric and congenital heart disease patients. Eur Heart J 2011; 32: 2236-2246.

545. Morady F., Kadish A.H., DiCarlo L. et al. Long-term results of catheter ablation of idiopathic right ventricu[ar tachycardia. Circulation 1990; 82: 2093-2099.

546. Yamashina Y., Yagi T., Namekawa A. et al. Distribution of successful ablation sites of idiopathic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2009; 32: 727-733.

547. Ventura R., Steven D., Klemm H.U. et al. Decennial follow-up in patients with recurrent tachycardia originating from the right ventricular outflow tract: electrophysiologic characteristics and response to treatment. Eur Heart J 2007; 28: 2338-2345.

548. Krittayaphong R., Sriratanasathavorn C., Dumavibhat C. et al. Electrocardiographic predictors of long-term outcomes after radiofrequency ablation in patients with right-ventricular outflow tract tachycardia. Europace 2006; 8: 601-606.

549. Steven D., Roberts-Thomson K.C., Seller J. et al. Ventricular tachycardia arising from the aortomitral continuity in structural heart disease: characteristics and therapeutic considerations for an anatomically challenging area of origin. Circ Arrhythm Electrophysiol 2009; 2: 660-666.

550. Hachiya H., Hirao K., Sasaki T. et al. Novel ECG predictor of difficult cases of outflow tract ventricular tachycardia: peak deflection index on an inferior lead. CircJ 2010; 74: 256-261.

551. Sachet F., Roberts-Thomson K., Tedrow U.L. et al. Epicardial ventricular tachycardia ablation a multicenter safety study.J Am Coil Cardiol 2010; 55: 2366-2372.

552. Ouyang F., Mathew S., Wu S. et al. Ventricu[ar arrhythmias arising from the [eft ventricular outflow tract below the aortic sinus cusps: mapping and catheter ablation via transseptal approach and electrocardiographic characteristics. Circ Arrhythm Electrophysiol 2014; 7: 445-455.

553. Kamakura S., Shimizu W., Matsuo K. et al. Localization of optimal ablation site of idiopathic ventricular tachycardia from right and left ventricular outflow tract by body surface ECG. Circulation 1998; 98: 1525-1533.

554. Callans D.J., Menz V., Schwartzman D. et al. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997; 29: 1023-1027.

555. Tada H., Hiratsuji T., Naito S. et al. Prevalence and characteristics of idiopathic outflow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outflow tract- Pacing Ciin Electrophysiol 2004; 27: 1240-1249.

556. Yamada T., McEIderry H.T., Doppalapudi H. et al. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coil Cardiol 2008; 52: 139-147.

557. Kanagaratnam L., Tomassoni G., Schweikert R. et al. Ventricular tachycardias arising from the aortic sinus of valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coil Cardiol 2001; 37: 1408-1414.

558. Ouyang F., Fotuhi P., Ha S.Y. et al. Repetitive mono-morphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation.J Am Coil Cardiol 2002; 39: 500-508.

559. Tada H., Nogami A., Naito S. et al. Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outflow tract tachycardia. Jpn Circ J 2001; 65: 723 -730.

560. Yamada T., Litovsky S.H., Kay G.N. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. CircArrhythm Electrophysio12008; 1: 396-404.

561. Yamada T., McEIderry H.T., Doppalapudi H. et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic concepts relevant to ablation. Circ Arrhythm Electrophysiol 2010; 3: 616-623.

562. Ouyang F., Bansch D., Schaumann A. et al. Catheter ablation of subepicardial ventricular tachycardia using electroanatomic mapping. Herz 2003; 28: 591-597.

563. Kumagai K., Yamauchi Y., Takahashi A. et al. Idiopathic left ventricular tachycardia originating from the mitral annulus. J Cardiovasc Electrophysiol 2005; 16: 1029-1036.

564. Tada H., Tadokoro K., Miyaji K. et al. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and topography of the arrhythmia origin. Heart Rhythm 2008; 5: 419-426

565. Sekiguchi Y., Aonuma K., Takahashi A. et al. Electrocardiographic and electrophysiologic characteristics of ventricular tachycardia originating within the pulmonary artery. J Am Coil Cardiol 2005; 45: 887-895.

566. Timmermans C., Rodriguez L.M., Crijns H.J. et al. Idiopathic left bundle-branch block-shaped ventricular tachycardia may originate above the pulmonary valve. Circulation 2003; 108: 1960-1967.

567. Krittayaphong R., Saiviroonporn P., Boonyasirinant T. et al. Magnetic resonance imaging abnormalities in right ventricular outflow tract tachycardia and the prediction of radiofrequency ablation outcome. Pacing Clin Electrophysiol 2006; 29: 837-845.

568. Prodemer A., Basadonna P.T., Slavich G.A. et al. Cardiac magnetic resonance imaging findings in patients with right ventricular outflow tract premature contractions. Eur Heart J 1997; 18: 2002- 2010.

569. Lerman B.B., Belardinelli L., West G.A., Berne R.M., DiMarco J.P. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986; 74: 270-280.

570. Lerman B.B. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation 1993; 87: 382-390.

571. Sung R.J., Keung E.C., Nguyen N.X., Huycke E.C. Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest 1988; 81: 688-699.

572. Wilber D.J., Baerman J., Olshansky B., Kall J., Kopp D. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 1993; 87: 126-134.

573. Marchlinski F.E., Deely M.P., Zado E.S. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J 2000; 139: 1009-1013.

574. O’Donne U.D., Cox D., Bourke J., Mitchell L., Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J 2003; 24: 801-810.

575. Khasnis A., Jongnarangsin K., Abela G. et al. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 2005; 28: 710-721.

576. H.O. Y.S. Overview of cardiac anatomy relevant to catheter ablation. In: Wilber D, Packer D, Stevenson W, eds. Catheter Ablation of Cardiac Arrhythmias, 3rd edn. Cambridge, MA: Blackwell Scientific; 2008: 3-17.

577. McAlpine W.A. Heart and Coronary Arteries. New Yorlc Springer-Verlag; 1975.

578. Ito S., Tada H., Naito S. et al. Development and validation of an ECG algorithm for identifying the optimal ablation site for idiopathic ventricular outflow tract tachycardia. J Cardiovasc Electrophysiol 2003; 14: 1280-1286.

579. Pons M., Beck L., Ledercq F. et al. Chronic left main coronary artery occlusion: a complication of radiofrequency ablation of idiopathic left ventricular tachycardia. Pacing Clin Electrophysio11997; 28: 1874-1876.

580. Koruth J.S., Aryana A., Dukkipati S.R. et al. Unusual complications of percutaneous epicardial access and epicardial mapping and ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol 2011; 4: 882-888.

581. Roberts-Thomson K.C., Steven D., Seller J. et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation 2009; 120: 1465-1473.

582. Makimoto H., Zhang Q., Tilz R.R. et al. Aborted sudden cardiac death due to radiofrequency ablation within the coronary sinus and subsequent total occlusion of the circumflex artery. J Cardiovasc Electrophysiol 2013; 24: 929-932.

583. Klein L.S., Shih H.T., Hackett F.K. et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 1992; 8S: 1666-1674.

584. Lin D., Hsia H.H., Gerstenfeld E.P. et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm 2005; 2: 934-939.

585. Crijns H.J., Smeets J.L., Rodriguez L.M. et al. Cure of interfascicular reentrant ventricular tachycardia by ablation of the anterior fascicle of the left bundle branch.J Cardiovasc Electrophysio11995; 6: 486-492.

586. Ohe T., Shimomura K., Aihara N. et al. Idiopathic sustained left ventricular tachycardia: clinical and electro-physiologic characteristics. Circulation 1988; 77: 560-568.

587. Ouyang F., Cappato R., Ernst S. et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the Purkinje network. Circulation 2002; 10S: 462-469.

588. Nogami A., Naito S., Tada H. et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamilsensitive idiopathic left ventriculartachycardia. J Am Coil Car-dio12000; 36: 811-823.

589. Ma F.S., Ma J., Tang K. et al. Left posterior fascicular block: a new endpoint of ablation for verapamil-sensitive idiopathic ventricular tachycardia. Chin Med J (Engl) 2006; 119: 367-372.

590. Kottkamp H., Chen X., Hindricks G. et al. Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysio11995; 18: 1285-129 7.

591. Nogami A., Naito S., Tada H. et al. et al. Verapamilsensitive left anterior fascicular ventricular tachycardia: results of radiofrequency ablation in six patients. J Cardiovasc Electrophysiol 1998; 9: 1269 - 1278.

592. Reithmann C., Hahnefeld A., Ulbrich M. et al. Different forms of ventricular tachycardia involving the left anterior fascicle in nonischemic cardiomyopathy: critical sites of the reentrant circuit in low-voltage areas. J Cardiovasc Electrophysiol 2009; 20: 841-849.

593. Bogun F., EI-Atassi R., Daoud E. et al. Radiofrequency ablation of idiopathic left anterior fascicular tachycardia. J Cardiovasc Electrophysio1199 5; 6: 1113-1116.

594. Mizusawa Y., Sakurada H., Nishizaki M. et al. Characteristics of bundle branch reentrant ventricular tachycardia with a right bundle branch block configuration: feasibility of atrial pacing. Europace 2009; 11: 1208-1213.

595. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol 2011; 34: 624-650.

596. Doppalapudi H., Yamada T., McElderry H.T. et al. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. CircArrhythm Electrophysiol 2008; 1: 23-29.

597. Crawford T., Mueller G., Good E. et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm 2010; 7: 725-730.

598. Bogun F., Desjardins B., Crawford T. et al. Post-infarction ventricular arrhythmias originating in papillary musdes.J Am Coil Cardiol 2008; S1: 1794-1802.

599. Yeh S.J., Wen M.S., Wang C.C., Lin F.C., Wu D. Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coil Cardio11997; 38: 1339-1345.

600. Kondo K., Watanabe I., Kojima T. et al. et al. Radiofrequency catheter ablation of ventricular tachycardia from the anterobasal left ventricle. Jpn Heart J 2000; 41: 215 -225.

601. Tada H., Ito S., Naito S. et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias.J Am Coil Cardiol 2005; 4S: 877-886.

602. Prystowsky E.N., Padanilam B.J., Joshi S., Fogel R.I. Ventricular arrhythmias in the absence of structural heart disease.J Am Coil Cardiol 2012; S?: 1733-1744.

603. Meissner M.D., Lehmann M.H., Steinman RT et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coil Cardio 1199 3; 21: 1406-1412.

604. Haissaguerre M., Shah D.C., Jais P et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet 2002; 3S9: 677-678.

605. Bogun F., Good E., Reich S. et al. Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coil Cardiol 2006; 48: 2500-2507.

606. Knecht S.A, Sugiyasu A., Kubota S., Kato K. Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system. Heart Rhythm 2005; 2: 646-649.

607. Haissaguerre M., Shoda M., Jais P. et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002; 106: 962-967.

608. Wever E.F., Robles de Medina E.O. Sudden death in patients without structural heart disease. J Am Coil Cardiol 2004; 43: 1137-1144.

609. Leenhardt A., Glaser E., Burguera M. et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994; 89: 206-215.

610. Eisenberg S.J., Scheinman M.M., Dullet et al. et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. AmJ Cardio11995; 75: 687-692.

611. Van den Branden B., Wever E., Boersma L. Torsade de pointes with short coupling interval. Acta Cardiol 2010; 65: 345-346.

612. Caforio A.L., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648.

613. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. CircJ 2011; 75: 734-743

614. Aoyama N., Izumi T., Hiramori K. et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fu[minant myocarditis (special report from a scientific committee). CircJ 2002; 66: 133-144.

615. Liberman L., Anderson B., Silver E.S. et al. Incidence and characteristics of arrhythmias in pediatric patients with myocarditis: a multicenter study. J Am Coil Cardiol 2014; 63: A483.

616. Kindermann I., Kindermann H., Kandolf R. et al. Predictors of outcome in patients with suspected myocardills. Circulation 2008; 118: 639-648.

617. Prochnau D., Surber R., Kuehnert H. et al. Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction. Clin Res Cardiol 2010; 99: 129-131.

618. Chung H.K. The role of the wearable cardioverter defibrillator in clinical practice. Cardiol Clin 2014; 32: 253-270.

619. Kandolin R., Lehtonen J., Salmenkivi K. et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Grc Heart Fail 2013; 6: 15-22.

620. Schumm J., Greulich S., Wagner A. et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 2014; 16: 14.

621. Rosenheck S., Weiss A., Sharon Z. Therapy success and survival in patients with valvular heart disease and implantable cardioverter defibrillator. IntJ Cardiol 2010; 144: 103-104.

622. Yang F., Shah B., Iwai S. et al. ICD implantation and arrhythmia-free survival in patients with depressed LV function following surgery for valvular heart disease. Pacing Clin Electrophysiol 2008; 31: 1419-1424.

623. Valles A.G., Khawaja F.J., Gersh B.J. et al. Implantable cardioverter defibrillators in patients with valvular car-diomyopathy.J Cardiovasc Electrophysiol 2012; 2.3: 1326-1332.

624. Aranki S.F., Santini F., Adams D.H. et al. Aortic valve endocarditis. Determinants of early survival and late morbidity. Circulation 1994; 90: 11175-11182.

625. Johnson L.L., Sciacca R.R., Ellis K. et al. Reduced left ventricular myocardial blood flow per unit mass in aortic stenosis. Circulation 1978; 57: 582-590.

626. Martinez-Rubio A., Schwammenthal Y., Schwammenthal E. et al. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and longterm follow-up. Circulation 1997; 96: 500-508.

627. Narasimhan C., Jazayeri M.R., Sra J. et al.Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation 1997; 96: 4307-4313.

628. Sagar S., Liu P.P., Cooper L.T. Jr. Myocarditis. Lancet 2012; 379: 738-747.

629. Liu Q.N., Reddy S., Sayre J.W. et al. Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T ceils in HIV type 1 myocarditis. AIDS Res Hum Retroviruses 2001; 17: 1423-1433.

630. Richardson P., McKenna W., Bristow P. et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.

631. Ukena C., Mahfoud F., Kindermann I et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis. EurJ Heart Fail 2011; 13: 398-405.

632. Kohno K., Aoyama N., Shimohama T. et al. Resuscitation from fulminant myocarditis associated with refractory ventricular fibrillation.Jpn CircJ 2000; 64: 139-143.

633. McCarthy R.E. 3rd, Boehmer J.P., Hruban R.H. et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N EngIJ Med 2000; 342.: 690-695.

634. Phillips M., Robinowitz M., Higgins J.R. et al. Sudden cardiac death in Air Force recruits. A 20-year review. JAP1A 1986; 256: 2696-2699.

635. Basso C., Calabrese F., Corrado D., Thiene G. Myocarditis: an underestimated cause of sudden cardiac death. In: Allot E., Clementy J., Prystowsky E.N., eds. Fighting Sudden Cardiac Death: A Worldwide Challenge. Armonk, NY: Futura; 2000: 447-458.

636. Basso C., Calabrese F., Corrado D., Thiene G. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovasc Res 2001; 50: 290-300

637. Fabre A., Sheppard M.N. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2006; 92: 316-320.

638. Wesslen L., Pahlson C., Lindquist O. et al. An increase in sudden unexpected cardiac deaths among young Swedish orienteers during 1979-1992. Eur Heart J 1996; 17: 902-910.

639. D’Ambrosio A., Patti G., Manzoli A. et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499-504.

640. Kuhl U., Pauschinger M., Seeberg B. et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112.: 1965 - 1970.

641. Plazzone P., Tsiachris D., Della Bella P. Epicardial management of myocarditisrelated ventricular tachycardia. Eur Heart J 2013; 34: 244.

642. Wallace S.M., Walton B.I., Kharbanda R.K. et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart 2002; 88: 53-60.

643. Kumar S., Barbhaiya C., Nagashima K. et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015; 8: 87-93.

644. Birnie D.H., Sauer W.H., Bogun F. et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305-1323.

645. von Olshausen K., Schwarz F., Apfelbach J. et al. Determinants of the incidence and severity of ventricular arrhythmias in aortic valve disease. Am J Cardio11983; 51: 1103-1109.

646. Hochreiter C., Niles N., Devereux R.B. et al. Mitral regurgitation: relationship of noninvasive descriptors of right and left ventricular performance to clinical and hemodynamic findings and to prognosis in medically and surgically treated patients. Circulation 1986; 73: 900-912.

647. Chizner H.A., Pearle D.L., deLeon A.C. Jr. The natural history of aortic stenosis in adults. Am Heart J 1980; 99: 419 -424.

648. Sorgato A., Faggiano P., Aurigemma G.P. et al. Ventricular arrhythmias in adult aortic stenosis: prevalence, mechanisms, and clinical relevance. Chest 1998; 113: 482-491.

649. Delahaye J.P., Gare J.P., Viguier E. et al. Natural history of severe mitral regurgitation. Eur Heart J 1991; 12(Suppl B): 5-9.

650. Grigioni F., Enriquez-Sarano M., Ling L.H. et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coil Cardio11999; 34: 2078-2085.

651. Olafiranye O., Hochreiter C.A., Borer J.S. et al. Nonischemic mitral regurgitation: prognostic value of nonsustained ventricular tachycardia after mitral valve surgery. Cardiology 2013; 124: 108-115.

652. Groves P. Valve disease: Surgery of valve disease: late results and late complications. Heart 2001; 86: 715 - 721.

653. Blackstone E.H., Kirklin J.W. Death and other time-related events after valve replacement. Circulation 1985; 72.: 753-767.

654. Hwang P1.H., Burchfiel C.M., Sethi G.K. et al. Comparison of the causes of late death following aortic and mitral valve replacement. VA Co-operative Study on Valvular Heart Disease. J Heart Valve Dis 1994; 3: 17-24.

655. Burke A.P., Farb A., Sessums L., Virmani R. Causes of sudden cardiac death in patients with replacement valves: an autopsy study.J Heart Valve Dis 1994; 3: 10-16.

656. Food and Drug Administration. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed P,eg 2005; 70: 61134-61135.

657. Watanabe J., Suzuki Y., Fukui N. et al. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour Hotter electrocardiogram recording study.J Clin Psychopharmacol 2012; 32: 18-22.

658. Wu C.S., Tsai Y.T., Tsai H.J. Antipsychotic drugs and the risk of ventricutar arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.J Am Heart Assoc 2015; 4: e001568.

659. Sala M., Vicentini A., Brambilla P. et al. QT interval prolongation related to psychoactive d rug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4: 1.

660. Fanoe S., Kristensen D., Fink-Jensen A. et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management- Eur Heart J 2014; 35: 1306-1315.

661. Girardin F.P., Gex-Fabry M., Bemey P. et al. Drug-induced tong QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. AmJ Psychiatry 2013; 170: 1468-1476.

662. Murray-Thomas T., Jones M.E., Patel D. et al. Risk of mortality (including sudden cardiac death) and major cardiovascutar events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol 2013; 2013: 247486.

663. Appleby L., Thomas S., Ferrier et al. Sudden unexplained death in psychiatric in-patients. 8rJ Psychiatry 2000; 176: 405-406

664. Poden D.M., Lazzara P., Rosen M. et al. Multipte mechanisms in the Iong-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94: 1996-2012.

665. Ray W.A., Meredith S., Thapa P.B. et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-1167.

666. Ray W.A., Chung C.P., Murray K.T. et al. Atypicat antipsychotic drugs and the risk of sudden cardiac death. N EngIJ Med 2009; 360: 225-235.

667. Haddad P.M., Anderson I.M. Antipsychotic-related QTc protongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-1671.

668. Taylor D.M. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107: 85-95.

669. Devinsky O. Sudden, unexpected death in epitepsy. N EngIJ Med 2011; 365: 1801-1811.

670. Annegers J.F. United States perspective on definitions and ctassifications. Epilepsid 1997; 38(Suppt): S9-S12.

671. Dasheiff P.M. Sudden unexpected death in epilepsy: a series from an epitepsy surgery program and speculation on the retationship to sudden cardiac death.J Clin Neuro-physio11991; 8: 216-222.

672. Donner E.J., Smith C.P., Snead O.C. 3rd. Sudden unexplained death in chitdren with epitepsy. Neurology 2001; 57: 430-434.

673. Ficker D.M., So E.L., Shen W.K. et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998; 51: 1270-1274.

674. Nashef L., Fish D.R., Garner S. et al. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and teaming difficulty. Epilepsia 1995; 36: 1187-1194.

675. Nitsson L., Ahtbom A., Farahmand B.Y., Tomson T. Mortatity in a population-based cohort of epitepsy surgery patients. Epilepsia 2003; 44: 575-581.

676. Sperling M.P., Feldman H., Kinman J., et al. Seizure control and mortality in epilepsy. Ann Neuro11999; 46: 45-50.

677. Tomson T., Nashef L., P,yvtin P. Sudden unexpected death in epilepsy: current knowtedge and futu re directions. Lancet Neurol 2008; 7: 1021 - 1031.

678. Tomson T., Watczak T., Sitlanpaa M., Sander J.W. Sudden unexpected death in epitepsy: a review of incidence and risk factors. Epilepsia 2005; 46(Suppl 11): 54-61.

679. Watczak T.S., Leppik I.E., D’Amelio M. et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001; 56: 519-525.

680. Sandorfi G., Ctemens B., Csanadi Z. Electrical storm in the brain and in the heart: epitepsy and Brugada syndrome. Mayo Clin Proc 2013; 88: 1167-1173.

681. Johnson J.N., Hofman N., Hagtund C.M. et al.Identification of a possible pathogenic rink between congenitat long QT syndrome and epitepsy. Neurology 2009; 72: 224-231.

682. Rugg-Gunn F.J., Simister P.J., Squirrell M. et al. Cardiac arrhythmias in focal epitepsy: a prospective tong-term study. Lancet 2004; 364: 2212-2219.

683. Pyvtin P., Nashef L., Lhatoo S.D. et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol 2013; 12: 966-977.

684. Lund M., Diaz L.J., Ranthe M.F. et al. Cardiac involvement in myotonic dystrophy: a nationwide cohort study. Eur Heart J 2014; 35: 2158-2164.

685. Groh W.J. Arrhythmias in the muscular dystrophies. Heart Rhythm 2012; 9: 1890-1895.

686. Petri H., Vissing J., Witting N. et al. Cardiac manifestations of myotonic dystrophy type 1. Int J Cardiol 2012; 160: 82-88.

687. Lallemand B., Ctementy N., Bernard-Brunet A. et al. The evotution of infrahissian conduction time in myotonic dystrophy patients: clinicat imptications. Heart 2012; 98: 291-296.

688. Groh W.J., Groh M.R., Saha C. et al. Etectrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N EngIJ Med 2008; 358: 2688-2697.

689. Roberts N.K., Perloff J.K., Kark R.A. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive extemat ophthatmoptegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. Am J Cardio11979; 44: 1396-1400.

690. Boriani G., Gatlina M., Merlini L. et al. Clinical relevance of atrial fibrillation/ flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term Iongitudinat study. Stroke 2003; 34: 901-908.

691. Wahbi K., Meune C., Porcher R. et al. Electrophysi-ological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012; 307: 1292-1301.

692. Laurent V., Petlieux S., Corcia P. et al. et al. Mortatity in myotonic dystrophy patients in the area of prophytactic pacing devices. IntJ Cardiol 2011; 150: 54-58.

693. Meune C., Van Berto J.H., Anselme F. et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N EnglJ Med 2006; 354: 209-210.

694. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Pegitz-Zagrosek V., Btomstrom Lundqvist C., Borghi C. et al. ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascutar diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147-3197.

695. Rashba E.J., Zareba W., Moss A.J. et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary tong QT syndrome. LQTS Investigators. Circulation 1998; 97: 451-456.

696. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-781.

697. Dorian P., Cass D., Schwartz B. et al. Amiodarone as compared with tidocaine for shock-resistant ventricutar fibrittation. N Engl J Med 2002; 346: 884-890.

698. Siu S.C., Sermer M, Cotman J.M. et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104: 515--521.

699. Drenthen W., Pieper P.G., Roos-Hessetink J.W. et al. Outcome of pregnancy in women with congenital heart disease: a literature review.J Am CoU Cardiol 2007; 47: 2303-2311.

700. Poos-Hessetink J.W., Puys T.P., Stein J.I. et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 2013; 34: 657-665.

701. Wotbrette D., Naccarelli G., Curtis A et al. Gender differences in arrhythmias. Clin Cardiol 2002; 25: 49-56.

702. Rodriguez-Manero M., Casado-Arroyo P., Sarkozy A. et al. The clinical significance of pregnancy in Brugada syndrome, flev Esp Cardiol (Engl Ed) 2014; 67: 176-180.

703. Benito B., Berruezo A. Brugada syndrome and pregnancy: delving into the role of sex hormones in ion chan-netopathies. Rev Esp Cardiol (Engl Ed) 2014; 67: 165-167.

704. Shotan A., Ostrzega E., Mehra A. et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. AmJ Cardio11997; 79: 1061-1064.

705. Widerhorn J., Widerhorn A.L., Rahimtoola S.H., Elkayam U. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123: 796-798.

706. Tawam M., Levine J., Mendelson M. et al. Effect of pregnancy on paroxysmal supraventricutar tachycardia. Am J Cardiol 1993; 72: 838-840.

707. Lee S.H., Chen S.A., Wu T.J., Chiang C.E. et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricutar tachycardia. Am J Cardio11995; 76: 675-678.

708. Brodsky M., Doria R., Allen B. et al. New-onset ventricutar tachycardia during pregnancy. Am Heart J 1992; 123: 933-941.

709. Silversides C.K., Harris L., Haberer K. et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. AmJ Cardiol 2006; 97: 1206-1212.

710. Sharif-Kazemi M.B., Ernkanjoo Z., Tavoosi A. et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Elec~rophysiol 2011; 34: el 8-e21.

711. Joglar J.A., Page R.L. Treatment of cardiac arrhythmias du ring pregnancy: safety considerations. Drug Saf 1999; 20: 85 -94.

712. Cox J.L., Gardner M.J. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36: 137-178.

713. Tan H.L., Lie K.I. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J 2001; 22: 458-464.

714. Abello M., Peinado R., Merino J.L. et al. Cardioverter defibrillator imptantationina pregnant woman guided with transesophageat ec h ocardiography. Pacing Clin Electrophysiol 2003; 26: 1913 - 1914.

715. Natale A., Davidson T., Geiger M.J., Newby K. Imptantable cardioverterdefibritlators and pregnancy: a safe combination? Circulation 1997; 96: 2808-2812.

716. Piper J.M., Berkus M., Ridgway L.E. 3rd. Pregnancy compticated by chronic cardiomyopathy and an automatic implantabte cardioverter defibritlator. Am J Obstet Gynecol 1992; 167: 506-507.

717. Sliwa K., Hilfiker-Kleiner D., Petrie M.C. et al. et al. Current state of knowtedge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Faiture Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767-778.

718. Cooper W.O., Hernandez-Diaz S., Arbogast P.G. et al. Major congenital matformations after first-trimester exposure to ACE inhibitors. N EnglJ Med 2006; 354: 2443-2451.

719. Regitz-Zagrosek V., Btomstrom Lundqvist C., Borghi C. et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147-3197.

720. Sliwa K., Fett J., Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368: 687-693.

721. Gunderson E.P., Croen L.A., Chiang V. et al. Epidemiotogy of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 2011; 118: 583-591.

722. Felker G.M., Jaeger C.J., Ktodas E. et al. Myocarditis and long-term survivat in peripartum cardiomyopathy.Am Heart J 2000; 140: 785-791.

723. van Spaendonck-Zwarts K.Y., Posafatvi A., van den Berg M.P. et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 2014; 35: 2165-2173.

724. Sliwa K., Hfiker-Kteiner D., Mebazaa A. et al. EURObservationat Research Programme: a wortdwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. EurJ Heart Fail 2014; 16: 583-591.

725. Gowda R.M., Khan I.A., Mehta N.J., et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. IntJ Cardio12003; 88: 129-133.

726. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003; 67: 591-594.

727. Trappe H.J., Pfitzner P. [Cardiac arrhythmias in pregnancy]. Z Kardiol 2001; 90(Supp[ 4): 36-44.

728. Mirshahi M., Ayani E., Nicolas C. et al. The blockade of mineralocorticoid hormone signaling provokes dramatic teratogenesis in cultured rat embryos. IntJ Toxicol 2002; 21: 191-199.

729. Habli M., O’Brien T., Nowack E. et al. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol 2008; 199: 415.e1-415.eS.

730. Willinger M., James L.S, Catz C. Defining the sudden infant death syndrome (SIDS 2000 ): deliberations of an expert panel convened by the National Institute of Child Health and Human Development // Pediatr Pathol. 1991. Vol. 11. P. 677-684.

731. Thach B. Tragic and sudden death: potential and proven mechanisms causing sudden infant death syndrome // EMBO Rep. 2008. Vol. 9. P. 114-118.

732. Sahni R., Fifer W.P., Myers M.M. Identifying infants at risk for sudden infant death syndrome // Curr Opin Pediatr. 2007. Vol. 19. P. 145-149.

733. Кравцова Л.А., Макаров Л.М., Школьникова М.А. Структура сна и сердечного ритма у детей первого года жизни // Рос.вестник перинатологии и педиатрии. 2000. Vol. 45. № 3. C. 35-38.

734. Guntheroth W.G., Spiers P.S. The triple risk hypotheses in sudden infant death syndrome // Pediatrics. 2002. Vol. 110. P. 64-65.

735. Кельмансон И.А. Сон, апноэ и риск нарушений ритма сердца у детей // Рос. вест. перин. и пед., 2000, 45, 3, с. 30-34.

736. Кравцова Л.А. Критерии риска и профилактика синдрома внезапной смерти у детей первого года жизни// Автореф. Диссер, Москва. 2000. 24с.

737. Schwartz P.J. Stillbirths. Sudden infant deaths, and long-QT syndrome: puzzle or mosaic, the pieces of the jigsaw are being fitted together // Circulation. 2004. Vol. 109. P. 2930-2932.

738. Tester D.J., Ackerman M.J. Sudden infant death syndrome: how significant are the cardiac channelopathies? // Cardiovasc Res. 2005. Vol. 67. Р. 388 -396.

739. Hunt C.E. Gene-environment interactions: implications for sudden unexpected deaths in infancy. Arch Dis Child. 2005; Vol. 90. P. 48 -53.

740. Moon R.Y., Darnall R.A., Feldman-Winter L. et al. SIDS and Other Sleep-Related Infant Deaths: Updated 2016. Recommendations for a Safe Infant Sleeping Environment. // PEDIATRICS Volume 138, number 5, November 2016, с 1-12.

741. Simantirakis E.N., Schiza S.I., Marketou M.E. et al. Severe bradyarrhythmias in patients with steep apnoea: the effect of continuous positive airway pressu re treatment: a longterm evaluation using an insertable loop recorder. Eur Heart J 2004; 25: 1070-1076.

742. Gami A.S., Otson E.J., Shen W.K. et al. Obstructive steep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults.J Am Coil Cardiol 2013; 62: 610-616.

743. Young T., Palta M., Dempsey J. et al. The occurrence of sleep disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-1235.

744. Marshall N.S., Wong K.K., Liu P.Y. et al. Steep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-1085.

745. Young T., Finn L., Peppard P.E. et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-1078.

746. Kreuz J., Skowasch D., Horlbeck F. et al. Usefulness of steep-disordered breathing to predict occurrence of appropriate and inappropriate imptantable-cardioverter defibrillator therapy in patients with imptantable cardioverter-defibrillator for primary prevention of sudden cardiac death. Am J Cardiol 2013; 111: 1319 - 1323.

747. Bitter T/, Westerheide N/, Prinz C/ et al. Cheyne-Stokes respiration and obstructive steep apnoea are independent risk factors for malignant ventricutar arrhythmias requiring appropriate cardioverter-defibrittator therapies in patients with congestive heart failure. Eur Heart J 2011; 32: 61-74.

748. Roche F/, Xuong A.N., Court-Fortune I et al. Relationship among the severity of steep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol 2003; 26: 669-677.

749. Guitleminault C., Connotly S.J., Winkle R.A. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with steep apnea syndrome. Am J Cardiol 1983; S2: 490-494.

750. Becker H.F., Koehter U., Stammnitz A., Peter J.H. Heart block in patients with sleep apnoea. Thorax 1998; S3(Suppl 3): S29-S32.

751. Grimm W., Hoffmann J., Menz V. et al. Electrophysiotogic evaluation of sinus node function and atrioventricutar conduction in patients with prolonged ven-tricutar asystole during obstructive sleep apnea. Am J Cardio11996; 77: 1310-1314.

752. Mehra R., Benjamin E.J., Shahar E. et al. Association of nocturnal arrhythmias with steep-disordered breathing: the Sleep Heart Health Study. AmJ Respir Crit Care Med 2006; 173: 910-916.

753. Hoffstein V., Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest 1994; 106: 466-471.

754. Tilkian A.G., Guilleminault C., Schroeder J.S. et al. Steep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med 1977; 63: 348-358.

755. Ryan C.M., Usui K., Floras J.S., Bradley T.D. Effect of continuous positive airway pressure on ventricutar ectopy in heart failure patients with obstructive sleep apnoea. Thorax 2005; 60: 781-785.

756. Gami A.S., Howard D.E., Otson E.J., Somers V.K. Daynight pattern of sudden death in obstructive sleep apnea. N EnglJ Med 2005; 352: 1206-1214.

757. Gonzatez-Rothi R.J., Foresman G.E., Block A.J. Do patients with sleep apnea die in their sleep? Chest 1988; 94: 531-538.

758. Seppata T., Partinen M., Penttila A. et al. Sudden death and sleeping history among Finnish men.J Intern Med 1991; 229: 23-28.

759. Zeidan-Shwiri T., Aronson D., Atalla K. et al. Circadian pattern of life-threatening ventricutar arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-defibriUators. Heart Rhythm 2011; 8: 657-662.

760. Harbison J., O’ReiUy P., McNichotas W.T. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest 2000; 118: 591-595.

761. Grimm W., Koehler U., Fus E. et al. Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway pressure therapy. Am J Cardiol 2000; 86: 688-692.

762. Koehter U., Fus E., Grimm W. et al. Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur RespirJ 1998; 11: 434-439.

763. Stegman S.S., Burroughs J.M., Henthorn R.W. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and treatment may reduce the need for pacemaker therapy. Pacing Clin Electro-physio11996; 19: 899- 904.

764. Garrigue S., Pepin J.L., Defaye P. et al. High prevalence of sleep apnea syndrome in patients with tong-term pacing: the European Multicenter Polysomnographic Study. Circulation 2007; 115: 1703-1709.

765. Doherty L.S., Kiely J.L., Swan V., McNicholas W.T. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127: 2076-2084.

766. Garrigue S., Bordier P., Jais P. et al. Benefit of atrial pacing in sleep apnea syndrome. N EngIJ Med 2002; 346: 404-412.

767. Simantirakis E.N., Vardas P.E. Cardiac pacing in sleep apnoea: diagnostic and therapeutic implications. Europace 2006; 8: 984-987.

768. Marin J.M., Carrizo S.J., Vicente E., Agusti A.G. Longterm cardiovascutar outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.

769. Defaye P., de ta Cruz I., Marti-Atmor J. et al. A pacemaker transthoracic impedance sensor with an advanced atgorithm to identify severe steep apnea: the DREAM European study. Heart Rhythm 2014; 11: 842-848.

770. Strotto P.J. J.R., Soose R.J., Maurer J.T. et al. Upper-airway stimulation for obstructive steep apnea. N Engl J Med 2014; 370: 139-149.

771. Wyse D.G., Friedman P.L., Brodsky M.A. et al. Life-threatening ventricular arrhythmias due to transient or cor-rectabte causes: high risk for death in follow-up.JAm Coil Cardiol 2001; 35: 1718-1724.

772. Monnig G., Kobe J., Loher A. et al. Role of imptantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term fottow-up. Europace 2012; 14: 396-401.

773. Wotbrette D.L. Risk of proarrhythmia with class III antiarrhythmic agents: sexbased differences and other issues. AmJ Cardiol 2003; 91: 39D-44D.

774. Haverkamp W., Breithardt G., Camm A.J. et al. The potential for QT protongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a poticy conference of the European Society of Cardiotogy. Eur Heart J 2000; 21: 1216-1231.

775. Rao G.A., Mann J.R., Shoaibi A. et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Faro Med 2014; 12: 121 - 127.

776. Ray W.A., Murray K.T., Hatl K. et al. Azithromycin and the risk of cardiovascutar death. N EngIJ Med 2012; 366: 1881 -1890.

777. Lapi F., Witchesky M., Kezouh A. et al. Ftuoroqui-notones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012; 55: 1457-1465.

778. Svanstrom H., Pastemak B., Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. 8MJ 2014; 347: g4930.

779. Fralick M., Macdonald E.M., Gomes T., et al. Canadian Drug Safety and Effectiveness Research Network (CDSERN). Co-trimoxazote and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349: g6196.

780. Tada H., Sticherling C., Orat H., Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001; 12: 275.

781. Lipshultz S.E., Lipsitz S.R., Mone S.M. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N EngIJ Med 1995; 332: 1738-1743.

782. Steinherz L.J., Steinherz P.G., Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Meal Pediatr Oncol 1995; 24: 352-361.

783. Anand A.J. Ftuorouracil cardiotoxicity. Ann Pharmacother 1994; 25: 374-378.

784. Gorgutu S., Cetik S., Tezel 4 -. A case of coronary spasm induced by 5-fluorouracil. Acta Cardiol 2002; 57: 381-383.

785. Pinter A., Dorian P., Newman D. Cesium-induced torsades de pointes. N EngIJ Med 2002; 346: 383-384.

786. Gowda RM, Cohen R.A., Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic imptications. Heart 2003; 89: e14.

787. Bain R.J. Accidentat digitalis poisoning due to drinking herbat tea. 8r MedJ (Clin Res Ed) 1985; 291): 1624.

788. Eddleston M., Ariaratnam C.A., Sjostrom L. et al. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, etectrolyte disturbances, and serum cardiac gtycoside concentrations on presentation to hospital. Heart 2000; 83: 301-306.

789. Schnetzter B., Popova N., Cotlao Lamb C., Sappino A.P. Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723-724.

790. Wetch K.M., Saiers J., Salonen R. Triptans and coronary spasm. Clin Pharmacol Ther 2000; 68: 337-338.

791. Qasim A., Townend J., Davies M.K. Ecstasy induced acute myocardiat infarction. Heart 2001; S5: E10.

792. Tzivoni D., Banal S., Schuger C. et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392-397.

793. Hondeghem L.M. Antiarrhythmic agents: modutated receptor applications. Circulation 1987; 75: 514-520.

794. Siebets J., Kuck K.H. Imptantable cardioverter defi-britlator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994; 127: 1139-1144.

795. Hellestrand K.J., Bumett P.J., Mitne J.R. et al. Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing threshotds. Pacing Clin Electro-physio11983; 6: 892-899.

796. Echt D.S., Btack J.N., Barbey J.T. et al. Evaluation of antiarrhythmic drugs on defibdtlation energy requirements in dogs. Sodium channel brock and action potentiat protongation. Circulation 1989; 77: 1106-1117.

797. Torp-Pedersen C., Molter M., Bloch-Thomsen P.E. et al. Dofetitide in patients with congestive heart failure and teft ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetitide Study Group. N EnglJ Med 1999; 341: 857-865.

798. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J 1993; 14(Suppl H): 88-92.

799. Макаров Л.М., Комолятова В.Н. Появление электрокардиографических признаков синдрома Бругада на фоне терапии антиаритмическим препаратом I С класса этацизином. Описание случая. Кардиология 2011; 4: 93-95.

800. Khan I.A., Gowda R.M. Novel therapeutics for treatment of tong-QT syndrome and torsade de pointes. Int J Cardiol 2004; 95: 1-6.

801. Barra S., Agarwal S., Begley D., Providencia R. Postacute management of the acquired tong QT syndrome. Postgrad MedJ 2014; 91): 348-358.

802. Borron S.W., Bismuth C., Muszynski J. Advances in the management of digoxin toxicity in the older patient. Drugs Aging 1997; 10: 18-33.

803. Sotomon R.J. Ventdcutar arrhythmias in patients with myocardial infarction and ischaemia. Relationship to serum potassium and magnesium. Drugs 1984; 28(Suppl 1): 66-76.

804. Sjogren A., Edvinsson L., Fatlgren B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias. J Intern Med 1989; 226: 213-222.

805. Rasmussen H.S., McNair P., Norregard P. et al. Intravenous magnesium in acute myocardiat infarction. Lancet 1986; 1: 234-236.

806. Abraham A.S., Rosenmann D., Kramer M. et al. et al. Magnesium in the prevention of tethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987; 147: 753-755.

807. Rajs J., Rajs E., Lundman L. Unexpected death in patients suffering from eating disorders. A medico-legal study. Acta Psychiatr Scand 1986; 74: 587-596.

808. Iseri L.T., Freed J., Bures A.R. Magnesium deficiency and cardiacdisorders.Am J Med 1975; 58: 837-846.

809. Zwerting H.K. Does exogenous magnesium suppress myocardiat irritabitity and tachyarrhythmias in the nondigitalized patient? Am Heart J 1987; 113: 1046-1053.

810. Rosenqvist M., Beyer T., Brock M. et al. Adverse events with transvenous implantabte cardioverter-defibritlators: a prospective mu tticenter study. European 7219 Jewel ICD investigators. Circulation 1998; 98: 663-670.

811. Sanchez M.J., Atberot G.A., Garrote AJ et al. et al. Ventricular arrhythmias induced by appropriate antibradycardia pacing in patients with imptantabte defibrillators]. Rev Esp Cardiol 2001; 54: 845-850.

812. Catlans D.J., Hook B.G., Kleiman R.B. et al. Unique sensing errors in third-generation implantable cardioverter-defibrittators. J Am Coll Cardiol 1993; 22: 1135-1140.

813. Chantranuwat C, Blakey J.D., Kobashigawa J.A. et al. Sudden, unexpected death in cardiac transptant recipients: an autopsy study. J Heart Lung Transplant 2004; 23: 683-689.

814. Vakil K., Taimeh Z., Sharma A. et al. et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm 2014; 11: 1684-1690.

815. Tsai V.W., Cooper J., Garan H. et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail 2009; 2: 197-201.

816. Menafoglio A., Di Valentino M., Porretta A.P. et al. Cardiovascular evaluation of middle-aged individuals engaged in high-intensity sport activities: implications for workload, yield and economic costs. BrJ Sports Med 2014 Nov 13. doi: 10.1136/bjsports-2014-093857 [Epub ahead of print].

817. Borjesson M., Serratosa L., Carre F. et al. Writing group on behalf of the EACPR Section of Sports Cardiology. Consensus document regarding cardiovascular safety at sports arenas: position stand from the European Association of Cardiovascular Prevention and Rehabilitation (EACPR), section of Sports Cardiology. Eur Heart J 2011; 32: 2119-2124.

818. Conroy R.M., Pyorala K., Fitzgerald A.P. et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.

819. Harmon K.G., Drezner J.A., Wilson I~IG, Sharma S. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Heart 2014; 100: 1227-1234.

820. Schmied C., Borjesson M. Sudden cardiac death in athletes.J Intern Med 2014; 275: 93-103.

821. Макаров Л.М. Внезапная смерть у молодых спортсменов. Кардиология. 2010; 50(2): 78-83.

822. Harmon K.G., Drezner J.A., Maleszewski JJ et al. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2): 198-204. doi: 10.1161/CIRCEP.113.001376.

823. Marijon E., Tafflet M., Celermajer D.S. et al. Sports-related sudden death in the general population. Circulation. 2011 Aug 9; 124(6): 672-81. doi: 10.1161/CIRCULATIONAHA.110.008979.

824. Bohm Ph., Scharhag J. and Meyer T. Data from a nationwide registry on sports-related sudden cardiac deaths in Germany. European Journal of Preventive Cardiology 2016, Vol. 23(6) 649-656. DOI: 10.1177/2047487315594087

825. Corrado D., Basso C., Pavei A. et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593 - 1601.

826. Maron B.J., Araujo C.G., Thompson P.D. et al. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2001; 103: 327-334.

827. Borjesson M., Urhausen A., Kouidi E. et al. Cardiovascular evaluation of middle-aged/senior individuals engaged in leisure-time sport activities: position stand from the sections of exercise physiology and sports cardiology of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prey Rehabil 2011; 18: 446-458.

828. Pappone C., Vicedomini G., Languso F. et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014; 130: 811-819.

829. Obeyesekere M.N., Leong-Sit P., Massel D. et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. Circulation 2012; 125: 2308-2315.

830. Munger T.M., Packer D.L., Hammill S.C. et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953 -1989. Circulation 1993; 87: 866-873.

831. Cohen M.I., Triedman J.K., Cannon B.C. et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9: 1006-1024.

832. Soumerai S.B., McLaughlin T.J., Spiegelman D. et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115 - 121.

833. Kong M.H., AI-Khatib S.M., Sanders G.D. et al. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. CardiolJ 2011; 15: 503-514.

834. Santangeli P., Di Biase L., Dello Russo A. et al. Meta-analysis: age and effectiveness of prophylactic implantable car-dioverter-defibrillators. Ann Intern Med 2010; 153: 592-599.

835. Healey J.S., Hallstrom A.P., Kuck K.H. et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28: 1746-1749.

836. Chan P.S., Nallamothu B.K., Spertus J.A. et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes 2009; 2: 16-24.

837. Brullmann S., Dichtl W., Paoli U. et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged >75 years versus those №75 years. AmJ Cardiol 2012; 107: 712-717.

838. Noyes K., Corona E., Zwanziger J. et al. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care 2007; 45: 377-385.

839. Lunney J.R, Lynn J., Foley D.J. et al. Patterns of functional decline at the end of life. JAMA 2003; 28?: 2387-2392.

840. Padeletti L., Arnar D.O., Boncinelli L. et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480-1489.

841. Jaarsma T., Beattie J.M., Ryder M. et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. EurJ Heart Fail 2009; 11: 433-443.

842. Goldstein N.E., Lampert R., Bradley E. et al. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med 2004; 141: 835-838.

843. Wright G.A., Klein G.J., Gula L.J. Ethical and legal perspective of implantable cardioverter defibrillator deactivation or implantable cardioverter defibrillator generator replacement in the elderly. Curr Opin Cardiol 2013; 28: 43-49.

844. Lampert R., Hayes D.L., Annas G.J. et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7: 1008-1026.

845. Рекомендации Национального Совета по реанимации, 2015 г. Адаптированный официальный перевод Рекомендаций Европейского Совета по реанимации по проведению реанимационных мероприятий 2015 года, под редакцией член-корр. РАН Мороз В.В. М.: Национальный совет по реанимации, 2016. 198.